MeSH term
Frequency | Condition_Probility | Aged | 549 | 1.0 |
Humans | 2203 | 0.0 |
Risk | 7 | 0.0 |
Time Factors | 113 | 1.0 |
Cohort Studies | 38 | 1.0 |
United States/epidemiology | 11 | 3.0 |
Immunohistochemistry | 23 | 0.0 |
Prognosis | 49 | 0.0 |
Recurrence | 23 | 1.0 |
African Continental Ancestry Group | 13 | 4.0 |
History, 20th Century | 4 | 2.0 |
United States | 7 | 0.0 |
Great Britain | 5 | 2.0 |
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use | 211 | 84.0 |
Diabetes Mellitus, Type 2/*drug therapy | 2 | 8.0 |
Diabetic Nephropathies/*drug therapy/mortality | 2 | 100.0 |
Randomized Controlled Trials | 46 | 10.0 |
Research Support, Non-U.S. Gov't | 794 | 0.0 |
Treatment Outcome | 83 | 2.0 |
Adrenergic beta-Antagonists/therapeutic use | 44 | 59.0 |
African Americans | 2 | 1.0 |
Angiotensin-Converting Enzyme Inhibitors/therapeutic use | 103 | 76.0 |
Antihypertensive Agents/therapeutic use | 33 | 35.0 |
Clinical Trials | 81 | 8.0 |
Hydralazine/therapeutic use | 4 | 66.0 |
Isosorbide Dinitrate/therapeutic use | 2 | 100.0 |
Risk Factors | 174 | 2.0 |
Adult | 694 | 1.0 |
Aged, 80 and over | 116 | 1.0 |
Cause of Death | 2 | 1.0 |
*Coronary Artery Bypass | 2 | 2.0 |
Endpoint Determination | 4 | 25.0 |
Female | 1011 | 1.0 |
Genotype | 287 | 2.0 |
Male | 1135 | 1.0 |
Middle Aged | 863 | 1.0 |
Peptidyl-Dipeptidase A/*genetics | 280 | 83.0 |
*Polymorphism, Genetic | 199 | 4.0 |
Prospective Studies | 70 | 1.0 |
Meta-Analysis | 4 | 2.0 |
Rats | 116 | 0.0 |
Rats, Inbred SHR | 21 | 25.0 |
Renin-Angiotensin System/physiology | 24 | 52.0 |
Ventricular Dysfunction, Left | 3 | 75.0 |
Cardiac Output, Low/*drug therapy | 2 | 100.0 |
Chronic Disease | 43 | 2.0 |
Drug Therapy, Combination | 97 | 6.0 |
Receptors, Angiotensin/*antagonists & inhibitors | 56 | 66.0 |
Tetrazoles/therapeutic use | 5 | 83.0 |
Valine/analogs & derivatives/therapeutic use | 2 | 66.0 |
Endopeptidases/metabolism | 3 | 2.0 |
Heart Failure, Congestive/drug therapy | 22 | 75.0 |
Hypertension/drug therapy | 53 | 86.0 |
Structure-Activity Relationship | 15 | 0.0 |
Angiotensin II/*physiology | 8 | 22.0 |
Animals | 410 | 0.0 |
Growth Substances/physiology | 2 | 1.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Receptor, Angiotensin, Type 1 | 43 | 34.0 |
Receptors, Angiotensin/metabolism | 3 | 20.0 |
Renin/metabolism | 4 | 33.0 |
Heart Failure, Congestive/*drug therapy | 43 | 74.0 |
*Physician's Practice Patterns | 6 | 33.0 |
Questionnaires | 13 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 171 | 0.0 |
Alleles | 136 | 1.0 |
Heterozygote | 7 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 8 | 1.0 |
Mast Cells/*enzymology | 2 | 7.0 |
Polymorphism, Genetic/physiology | 6 | 22.0 |
*Variation (Genetics) | 6 | 0.0 |
Acute Disease | 18 | 0.0 |
Analysis of Variance | 38 | 1.0 |
Disease Models, Animal | 15 | 0.0 |
Hamsters | 26 | 0.0 |
Protease Inhibitors/*therapeutic use | 7 | 28.0 |
Serine Endopeptidases/*metabolism | 7 | 7.0 |
Polymerase Chain Reaction | 78 | 0.0 |
Asian Continental Ancestry Group/genetics | 7 | 2.0 |
Gene Frequency | 88 | 1.0 |
Japan | 17 | 1.0 |
Peptidyl-Dipeptidase A/genetics | 49 | 61.0 |
Reference Values | 52 | 1.0 |
Risk Assessment | 5 | 0.0 |
Physical Endurance | 2 | 6.0 |
*Sports | 3 | 9.0 |
Adolescent | 128 | 0.0 |
Albuminuria/urine | 3 | 15.0 |
Case-Control Studies | 70 | 1.0 |
Child | 59 | 0.0 |
Child, Preschool | 33 | 0.0 |
Creatinine/blood | 28 | 9.0 |
Follow-Up Studies | 63 | 1.0 |
Infant | 19 | 0.0 |
Kidney Function Tests | 19 | 15.0 |
Polymorphism, Genetic/genetics | 16 | 2.0 |
Angiotensin-Converting Enzyme Inhibitors/*pharmacology/therapeutic use | 23 | 76.0 |
Antihypertensive Agents/*pharmacology/therapeutic use | 6 | 85.0 |
English Abstract | 229 | 1.0 |
Hypertension/drug therapy/*physiopathology | 13 | 92.0 |
Receptor, Angiotensin, Type 2 | 27 | 35.0 |
Receptors, Angiotensin/*antagonists & inhibitors/metabolism | 5 | 83.0 |
Renin-Angiotensin System/*drug effects/physiology | 10 | 66.0 |
Calcium Channel Blockers/*pharmacology | 4 | 11.0 |
Cells, Cultured | 49 | 0.0 |
Comparative Study | 383 | 1.0 |
Endothelium, Vascular/enzymology | 9 | 20.0 |
Nitric Oxide/*metabolism | 3 | 2.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Peptidyl-Dipeptidase A/blood | 63 | 81.0 |
Rabbits | 33 | 1.0 |
Receptor, Bradykinin B2 | 4 | 19.0 |
Vasodilation/*drug effects | 9 | 23.0 |
Angiotensinogen/genetics/metabolism | 3 | 60.0 |
*Gene Expression | 7 | 0.0 |
Peptidyl-Dipeptidase A/genetics/metabolism | 4 | 80.0 |
RNA, Messenger/metabolism | 13 | 0.0 |
Receptors, Angiotensin/genetics/metabolism | 4 | 100.0 |
Renin-Angiotensin System/*genetics | 24 | 51.0 |
Antihypertensive Agents/administration & dosage/*therapeutic use | 7 | 53.0 |
Enalapril/*therapeutic use | 39 | 78.0 |
Hypertension/*drug therapy | 131 | 79.0 |
Captopril/*therapeutic use | 28 | 71.0 |
Myocardial Infarction/*drug therapy/physiopathology/ultrasonography | 2 | 100.0 |
Ventricular Function, Left/*drug effects | 7 | 70.0 |
Hypertension/*genetics | 19 | 17.0 |
Polymorphism, Genetic | 90 | 2.0 |
Age Factors | 36 | 1.0 |
Angiotensin-Converting Enzyme Inhibitors/administration & dosage | 8 | 72.0 |
Antihypertensive Agents/administration & dosage | 3 | 30.0 |
Blood Pressure/drug effects | 200 | 35.0 |
Dose-Response Relationship, Drug | 78 | 1.0 |
Drug Administration Schedule | 24 | 2.0 |
Drug Evaluation | 13 | 5.0 |
Incidence | 19 | 1.0 |
Severity of Illness Index | 19 | 1.0 |
Sex Factors | 17 | 1.0 |
Statistics | 4 | 0.0 |
Albuminuria/*prevention & control | 2 | 2.0 |
Angiotensin II/*antagonists & inhibitors | 18 | 69.0 |
Antihypertensive Agents/pharmacology/*therapeutic use | 7 | 46.0 |
Angiotensin-Converting Enzyme Inhibitors/*diagnostic use | 4 | 100.0 |
Captopril/*diagnostic use | 10 | 100.0 |
Hypertension, Renovascular/etiology/*radionuclide imaging | 2 | 100.0 |
Reproducibility of Results | 10 | 0.0 |
Sensitivity and Specificity | 17 | 0.0 |
Biological Transport | 5 | 0.0 |
Chromatography, High Pressure Liquid | 24 | 1.0 |
Hydrolysis | 30 | 3.0 |
Oligopeptides/*metabolism | 8 | 25.0 |
Amino Acid Sequence | 59 | 0.0 |
Angiotensin-Converting Enzyme Inhibitors/*pharmacology | 121 | 84.0 |
CHO Cells | 17 | 0.0 |
Fluorescent Dyes | 3 | 0.0 |
In Vitro | 44 | 0.0 |
Kinetics | 69 | 0.0 |
Lisinopril/pharmacology | 6 | 60.0 |
Models, Biological | 6 | 0.0 |
Mutation | 11 | 0.0 |
Peptidyl-Dipeptidase A/*chemistry/genetics/metabolism | 2 | 100.0 |
Protein Structure, Tertiary | 13 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Substrate Specificity | 33 | 1.0 |
Exercise/*physiology | 13 | 3.0 |
Exercise Test | 19 | 7.0 |
Heart Rate/physiology | 3 | 3.0 |
Homozygote | 10 | 0.0 |
Military Personnel | 3 | 9.0 |
Oxygen Consumption/genetics | 3 | 50.0 |
Physical Endurance/*genetics | 5 | 71.0 |
Animals, Genetically Modified | 4 | 1.0 |
Environment | 2 | 2.0 |
*Gene Therapy | 3 | 0.0 |
Polymorphism, Genetic/*genetics | 67 | 5.0 |
Gene Expression/drug effects | 2 | 0.0 |
Neovascularization, Pathologic/*drug therapy | 2 | 4.0 |
Perindopril/*therapeutic use | 4 | 100.0 |
Angiotensin-Converting Enzyme Inhibitors/pharmacology | 51 | 63.0 |
Captopril/pharmacology | 43 | 76.0 |
Peptidyl-Dipeptidase A/*analysis | 14 | 87.0 |
Pregnancy | 44 | 0.0 |
Angiotensin II Type 1 Receptor Blockers | 2 | 18.0 |
Angiotensin-Converting Enzyme Inhibitors/chemistry/pharmacology | 2 | 66.0 |
Models, Molecular | 7 | 0.0 |
Protein Conformation | 8 | 0.0 |
Spermatozoa/enzymology | 3 | 30.0 |
Testis/enzymology | 12 | 23.0 |
Antihypertensive Agents/*therapeutic use | 89 | 40.0 |
Benzimidazoles/*therapeutic use | 4 | 33.0 |
Endothelium, Vascular/drug effects | 6 | 10.0 |
Exercise Tolerance/drug effects | 2 | 33.0 |
Heart Rate/drug effects | 55 | 22.0 |
Stroke Volume/drug effects | 7 | 23.0 |
Tetrazoles/*therapeutic use | 4 | 26.0 |
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use | 3 | 6.0 |
Diabetes Mellitus, Type 2/*complications | 6 | 15.0 |
Retrospective Studies | 53 | 1.0 |
Amyloid beta-Protein Precursor/*metabolism | 2 | 2.0 |
Cell Line | 18 | 0.0 |
Endopeptidases/*metabolism | 11 | 8.0 |
Hydroxamic Acids/*pharmacology | 2 | 4.0 |
Neurons | 2 | 13.0 |
Peptidyl-Dipeptidase A/*metabolism | 84 | 90.0 |
Protease Inhibitors/*pharmacology | 3 | 6.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Transfection | 14 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism | 2 | 0.0 |
Cardiac Output, Low/*drug therapy/mortality | 2 | 100.0 |
Physician's Practice Patterns | 3 | 7.0 |
Systole | 11 | 13.0 |
Drug Interactions | 30 | 2.0 |
Kidney Diseases/metabolism | 3 | 11.0 |
Liver Diseases/metabolism | 3 | 17.0 |
Renin-Angiotensin System/drug effects/physiology | 15 | 68.0 |
Apolipoproteins E/genetics | 13 | 4.0 |
Carotid Arteries/*ultrasonography | 4 | 26.0 |
DNA Transposable Elements | 20 | 14.0 |
Gene Deletion | 44 | 2.0 |
Longitudinal Studies | 9 | 1.0 |
Solubility | 5 | 0.0 |
DNA/genetics | 14 | 0.0 |
Family Health | 2 | 0.0 |
Mutagenesis, Insertional | 14 | 4.0 |
Sequence Deletion | 25 | 1.0 |
Double-Blind Method | 141 | 8.0 |
Heart Failure, Congestive/*drug therapy/physiopathology | 28 | 82.0 |
Blood Pressure | 47 | 7.0 |
Crystallography, X-Ray | 2 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Models, Chemical | 2 | 0.0 |
Peptides/chemistry | 4 | 1.0 |
Peptidyl-Dipeptidase A/*chemistry | 4 | 100.0 |
Protein Binding | 11 | 0.0 |
Stereoisomerism | 2 | 0.0 |
Hydrolysis/drug effects | 2 | 8.0 |
Mice | 36 | 0.0 |
Oligopeptides/blood/*metabolism/urine | 2 | 100.0 |
Peptidyl-Dipeptidase A/chemistry/*metabolism | 4 | 80.0 |
Genetic Predisposition to Disease | 30 | 1.0 |
Molecular Biology | 2 | 0.0 |
Peptidyl-Dipeptidase A/*genetics/physiology | 9 | 90.0 |
Antihypertensive Agents/adverse effects/*pharmacology | 2 | 66.0 |
Diuretics/therapeutic use | 40 | 75.0 |
Hospitalization | 9 | 7.0 |
Multicenter Studies | 9 | 7.0 |
Quality of Life | 17 | 10.0 |
Receptors, Angiotensin/*antagonists & inhibitors/physiology | 3 | 75.0 |
Spironolactone/therapeutic use | 2 | 14.0 |
Survival Analysis | 17 | 0.0 |
Drug Synergism | 20 | 1.0 |
Neprilysin/*antagonists & inhibitors | 7 | 70.0 |
Pyridines/pharmacology | 4 | 1.0 |
Receptors, Angiotensin/*genetics | 13 | 28.0 |
Antibody Specificity | 4 | 0.0 |
Cell Membrane/enzymology | 8 | 3.0 |
Peptidyl-Dipeptidase A/immunology/*metabolism | 4 | 100.0 |
Serine Proteinase Inhibitors/pharmacology | 2 | 4.0 |
Umbilical Veins | 6 | 1.0 |
Asian Continental Ancestry Group/*genetics | 7 | 2.0 |
Polymerase Chain Reaction/methods | 10 | 0.0 |
Polymorphism, Restriction Fragment Length | 8 | 0.0 |
Singapore | 2 | 4.0 |
Testis/*enzymology | 7 | 18.0 |
Disease Progression | 30 | 1.0 |
Hypertension/*complications | 3 | 17.0 |
Kidney Diseases/physiopathology | 2 | 28.0 |
Angiotensin II/physiology | 7 | 30.0 |
Renin-Angiotensin System/*physiology | 31 | 55.0 |
Asian Continental Ancestry Group | 6 | 2.0 |
China/epidemiology | 3 | 1.0 |
Coronary Disease/enzymology/*epidemiology/*genetics | 2 | 100.0 |
Infant, Newborn | 16 | 0.0 |
Peptidyl-Dipeptidase A/*blood | 109 | 91.0 |
Albuminuria/*drug therapy/urine | 2 | 100.0 |
Enalapril/*pharmacology/therapeutic use | 3 | 50.0 |
Hemoglobin A, Glycosylated/analysis | 6 | 1.0 |
India | 3 | 0.0 |
*Gene Deletion | 43 | 5.0 |
Genetic Markers | 22 | 0.0 |
Peptidyl-Dipeptidase A/blood/*genetics | 37 | 90.0 |
*Angioplasty, Transluminal, Percutaneous Coronary | 7 | 15.0 |
Angiotensinogen/*genetics | 25 | 28.0 |
Isoquinolines/*therapeutic use | 5 | 45.0 |
Receptors, Angiotensin/genetics | 14 | 56.0 |
*Tetrahydroisoquinolines | 34 | 55.0 |
Receptors, LDL/*genetics | 2 | 1.0 |
*Diabetes Complications | 6 | 10.0 |
Diabetes Mellitus/drug therapy | 5 | 45.0 |
Diabetic Angiopathies/*prevention & control | 2 | 40.0 |
Hypertension/*prevention & control | 2 | 20.0 |
Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics | 3 | 100.0 |
Endothelium, Vascular/*physiology | 2 | 1.0 |
Peptidyl-Dipeptidase A/*analysis/blood | 5 | 100.0 |
*Alleles | 10 | 0.0 |
Enalaprilat/*pharmacology | 4 | 66.0 |
Endothelium, Vascular/*enzymology | 3 | 6.0 |
Lung/blood supply/*enzymology | 2 | 66.0 |
Peptidyl-Dipeptidase A/blood/metabolism | 3 | 75.0 |
Angiotensin II/*metabolism | 17 | 36.0 |
Antihypertensive Agents/adverse effects/pharmacokinetics/*therapeutic use | 2 | 100.0 |
Angiotensin-Converting Enzyme Inhibitors/pharmacology/therapeutic use | 9 | 64.0 |
Cardiovascular Diseases/*physiopathology | 2 | 18.0 |
Endothelium, Vascular/metabolism | 4 | 1.0 |
Fibrinolysis/drug effects | 3 | 7.0 |
Nitric Oxide/metabolism | 4 | 2.0 |
Plasminogen Activator Inhibitor 1/metabolism | 2 | 4.0 |
Tissue Plasminogen Activator/metabolism | 2 | 5.0 |
Angiotensin I/metabolism | 14 | 66.0 |
Forecasting | 11 | 3.0 |
Renin-Angiotensin System/drug effects | 49 | 74.0 |
Aldosterone/*secretion | 2 | 22.0 |
Aldosterone Antagonists/*therapeutic use | 2 | 66.0 |
Endothelins/metabolism | 2 | 25.0 |
Heart Failure, Congestive/drug therapy/metabolism | 2 | 50.0 |
Morbidity | 5 | 8.0 |
Receptors, Endothelin/antagonists & inhibitors | 2 | 22.0 |
Spironolactone/*therapeutic use | 3 | 42.0 |
Acetylcholine/pharmacology | 6 | 8.0 |
Calcium Channel Blockers/*therapeutic use | 22 | 73.0 |
Cilazapril/therapeutic use | 2 | 100.0 |
Endothelium, Vascular/*physiopathology | 4 | 4.0 |
Hypertension/*drug therapy/physiopathology | 60 | 82.0 |
Lisinopril/therapeutic use | 7 | 70.0 |
Losartan/therapeutic use | 2 | 40.0 |
Nifedipine/therapeutic use | 5 | 83.0 |
Receptors, Angiotensin/antagonists & inhibitors | 22 | 44.0 |
Vasoconstriction/drug effects | 7 | 18.0 |
Vasodilator Agents/pharmacology | 4 | 6.0 |
Randomized Controlled Trials/*methods | 2 | 50.0 |
Mutagenesis, Insertional/*genetics | 2 | 6.0 |
Calibration | 2 | 1.0 |
Indicators and Reagents | 2 | 0.0 |
Rats, Wistar | 10 | 0.0 |
Spectrophotometry, Ultraviolet | 3 | 1.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
*Mutagenesis, Insertional | 4 | 11.0 |
Aging/*physiology | 11 | 4.0 |
Glucose Tolerance Test | 6 | 1.0 |
*Physical Education and Training | 2 | 3.0 |
*Sex Characteristics | 2 | 1.0 |
Gene Frequency/genetics | 7 | 1.0 |
Italy/epidemiology | 5 | 2.0 |
Logistic Models | 9 | 1.0 |
Multivariate Analysis | 13 | 0.0 |
Phenotype | 26 | 0.0 |
Predictive Value of Tests | 9 | 0.0 |
Endothelium, Vascular/drug effects/metabolism | 2 | 3.0 |
Enzyme Inhibitors/*therapeutic use | 3 | 3.0 |
Kidney/physiopathology | 6 | 10.0 |
Angiotensin II/blood | 21 | 36.0 |
Aging/genetics/metabolism | 2 | 13.0 |
Aldosterone/blood | 43 | 22.0 |
Blood Pressure/genetics | 6 | 16.0 |
Diet, Sodium-Restricted | 7 | 23.0 |
Peptidyl-Dipeptidase A/*genetics/metabolism | 13 | 72.0 |
Renin/blood | 87 | 28.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 20 | 0.0 |
Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use | 8 | 88.0 |
Cardiovascular Agents/adverse effects/*therapeutic use | 3 | 100.0 |
Cardiovascular Diseases/*drug therapy | 9 | 75.0 |
Renin/antagonists & inhibitors | 7 | 100.0 |
Alu Elements/*genetics | 4 | 12.0 |
Russia | 6 | 6.0 |
Amine Oxidoreductases/genetics | 4 | 3.0 |
Aryldialkylphosphatase | 2 | 1.0 |
*Chromosome Mapping | 5 | 0.0 |
Esterases/genetics | 2 | 11.0 |
European Continental Ancestry Group/*genetics | 5 | 1.0 |
Heterotrimeric GTP-Binding Proteins/*genetics | 2 | 4.0 |
Hypertrophy, Left Ventricular/*genetics | 6 | 75.0 |
Isoenzymes/genetics | 2 | 0.0 |
Methylenetetrahydrofolate Reductase (NADPH2) | 9 | 1.0 |
United Arab Emirates | 2 | 20.0 |
Antilipemic Agents/therapeutic use | 2 | 6.0 |
Calcium Channel Blockers/therapeutic use | 32 | 78.0 |
Cardiotonic Agents/therapeutic use | 8 | 66.0 |
Digoxin/therapeutic use | 8 | 61.0 |
Myocardial Ischemia/*drug therapy | 4 | 36.0 |
Myocardial Revascularization | 2 | 22.0 |
Nitrates/therapeutic use | 6 | 100.0 |
Patient Selection | 5 | 2.0 |
Thrombolytic Therapy | 4 | 22.0 |
Blotting, Northern | 3 | 0.0 |
Dogs | 18 | 1.0 |
Enalapril/pharmacology | 21 | 75.0 |
Hemodynamic Processes/drug effects | 64 | 38.0 |
Hormones/blood | 5 | 4.0 |
In Situ Hybridization | 5 | 0.0 |
Myocardium/*metabolism | 6 | 2.0 |
Ventricular Function, Left | 6 | 19.0 |
Antihypertensive Agents/adverse effects/*therapeutic use | 9 | 100.0 |
Calcium Channel Blockers/adverse effects/*therapeutic use | 6 | 75.0 |
Hypertension/*drug therapy/*etiology | 2 | 100.0 |
Immunosuppressive Agents/therapeutic use | 4 | 1.0 |
Kidney/*physiopathology | 8 | 13.0 |
Kidney Transplantation/*adverse effects | 5 | 8.0 |
Lisinopril/adverse effects/*therapeutic use | 2 | 100.0 |
Algorithms | 2 | 0.0 |
Kidney Diseases/drug therapy | 5 | 83.0 |
*Meta-Analysis | 2 | 22.0 |
*Models, Statistical | 2 | 3.0 |
Regression Analysis | 24 | 1.0 |
*Treatment Outcome | 2 | 8.0 |
Base Sequence | 57 | 0.0 |
Gene Expression | 5 | 0.0 |
Genes, Viral | 2 | 0.0 |
Hydrogen-Ion Concentration | 16 | 1.0 |
Age Distribution | 6 | 1.0 |
Gene Expression Profiling/methods | 2 | 2.0 |
Sex Distribution | 6 | 2.0 |
Variation (Genetics)/genetics | 2 | 1.0 |
Pilot Projects | 12 | 1.0 |
Genetic Vectors | 3 | 0.0 |
Plasmids | 2 | 0.0 |
Health Care Surveys | 2 | 16.0 |
Angiotensin II/antagonists & inhibitors | 14 | 93.0 |
Atrial Natriuretic Factor/pharmacology | 2 | 11.0 |
Biological Markers/analysis | 4 | 0.0 |
Diagnosis, Differential | 19 | 0.0 |
Renin-Angiotensin System/drug effects/*physiology | 8 | 80.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Hypertension/*drug therapy/metabolism | 8 | 61.0 |
Triglycerides/*blood | 2 | 0.0 |
Contraceptives, Oral/*adverse effects | 2 | 9.0 |
Factor V/*genetics | 4 | 2.0 |
Alzheimer Disease/*genetics | 5 | 1.0 |
Coronary Arteriosclerosis/*genetics | 3 | 13.0 |
Antihypertensive Agents/*pharmacology | 21 | 47.0 |
Atrial Natriuretic Factor/drug effects | 2 | 66.0 |
Thiazepines/*pharmacology | 3 | 50.0 |
Vasodilator Agents/*pharmacology | 2 | 4.0 |
Ramipril/*therapeutic use | 7 | 77.0 |
Aging | 2 | 0.0 |
Apolipoproteins C/genetics | 2 | 5.0 |
Lipoproteins, LDL Cholesterol/blood | 8 | 1.0 |
Sex Characteristics | 11 | 2.0 |
Smoking | 4 | 1.0 |
Variation (Genetics) | 14 | 0.0 |
Adrenergic beta-Antagonists/adverse effects/therapeutic use | 5 | 83.0 |
Cerebrovascular Accident/prevention & control | 2 | 25.0 |
*Clinical Trials | 6 | 28.0 |
Diuretics/adverse effects/therapeutic use | 2 | 100.0 |
Hypertension/*drug therapy/mortality | 4 | 100.0 |
Haplotypes | 5 | 0.0 |
Spain | 2 | 0.0 |
Angiotensin-Converting Enzyme Inhibitors/*adverse effects | 39 | 86.0 |
Prescriptions, Drug/*statistics & numerical data | 2 | 50.0 |
African Continental Ancestry Group/*genetics | 10 | 3.0 |
Tunica Intima/ultrasonography | 3 | 15.0 |
Tunica Media/ultrasonography | 3 | 17.0 |
Feasibility Studies | 2 | 0.0 |
Magnetic Resonance Imaging | 8 | 0.0 |
Radioisotope Renography/*methods | 5 | 83.0 |
Renal Artery Obstruction/*radionuclide imaging | 3 | 100.0 |
Cardiotonic Agents/*therapeutic use | 2 | 33.0 |
Cross-Over Studies | 30 | 4.0 |
Heart Failure, Congestive/*drug therapy/mortality/physiopathology | 9 | 81.0 |
*Heart Rate | 3 | 6.0 |
Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use | 44 | 93.0 |
Drug Combinations | 13 | 2.0 |
Drug Resistance | 7 | 1.0 |
Hydrochlorothiazide/adverse effects/*therapeutic use | 3 | 100.0 |
Tetrazoles/adverse effects/*therapeutic use | 2 | 100.0 |
*Blood Pressure | 12 | 9.0 |
Diastole | 10 | 14.0 |
Angiotensin II/metabolism | 11 | 26.0 |
Hospital Mortality | 4 | 12.0 |
Brain Ischemia/*genetics | 4 | 28.0 |
Cerebrovascular Accident/*genetics | 2 | 13.0 |
*DNA Transposable Elements | 6 | 11.0 |
Atenolol/therapeutic use | 4 | 40.0 |
Biphenyl Compounds/*therapeutic use | 4 | 57.0 |
Blood Pressure/*drug effects | 52 | 33.0 |
Hypertension/*drug therapy/*genetics | 2 | 100.0 |
Polymorphism, Genetic/*physiology | 5 | 7.0 |
Angiotensin-Converting Enzyme Inhibitors/economics/therapeutic use | 2 | 100.0 |
Hypertension/*drug therapy/economics | 3 | 100.0 |
Cardiovascular Diseases/genetics | 2 | 7.0 |
*Molecular Biology | 2 | 5.0 |
Pharmacogenetics | 2 | 1.0 |
Norway | 4 | 3.0 |
Calcium Channel Blockers/adverse effects/therapeutic use | 6 | 100.0 |
Emergencies | 3 | 15.0 |
England/epidemiology | 5 | 9.0 |
Medical Record Linkage | 2 | 50.0 |
Odds Ratio | 27 | 2.0 |
Angioneurotic Edema/*chemically induced | 7 | 100.0 |
Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use | 10 | 100.0 |
Blood Donors | 2 | 0.0 |
European Continental Ancestry Group/genetics | 11 | 1.0 |
Factor V/genetics | 3 | 3.0 |
Prevalence | 30 | 2.0 |
Prothrombin/genetics | 3 | 4.0 |
Heart Diseases/drug therapy | 3 | 75.0 |
Spermatozoa/*enzymology | 2 | 12.0 |
Angiotensin II/antagonists & inhibitors/*physiology | 2 | 100.0 |
Hypertension/drug therapy/physiopathology | 10 | 62.0 |
Hypertension, Renovascular/drug therapy/physiopathology | 5 | 100.0 |
Kidney/drug effects/*physiology/physiopathology | 3 | 100.0 |
Sodium, Dietary | 2 | 66.0 |
Pentetic Acid/diagnostic use | 4 | 30.0 |
Succimer/diagnostic use | 3 | 50.0 |
Aldosterone Synthase/*genetics | 4 | 5.0 |
Cross-Sectional Studies | 19 | 1.0 |
Epistasis, Genetic | 3 | 5.0 |
Physical Endurance/genetics | 2 | 66.0 |
Coronary Disease/*genetics | 10 | 16.0 |
*Genetic Markers | 3 | 0.0 |
*Linkage Disequilibrium | 2 | 1.0 |
Adrenergic beta-Antagonists/*therapeutic use | 11 | 29.0 |
Carbazoles/*therapeutic use | 2 | 33.0 |
Echocardiography | 32 | 15.0 |
Propanolamines/*therapeutic use | 5 | 31.0 |
Research Design | 8 | 9.0 |
Ventricular Remodeling/*drug effects | 3 | 100.0 |
Antihypertensive Agents/economics/*therapeutic use | 2 | 100.0 |
Bahrain | 2 | 50.0 |
Guidelines | 2 | 7.0 |
Physicians, Family | 2 | 22.0 |
Prescriptions, Drug | 2 | 25.0 |
Perindopril/therapeutic use | 3 | 75.0 |
Kuwait | 2 | 8.0 |
Immune Sera | 2 | 0.0 |
Angiotensin-Converting Enzyme Inhibitors/adverse effects | 7 | 77.0 |
Data Collection | 6 | 7.0 |
Organ Size | 2 | 1.0 |
Angiotensin II Type 1 Receptor Blockers/therapeutic use | 2 | 66.0 |
Blood Vessels/pathology | 2 | 5.0 |
Hypertension/enzymology | 3 | 30.0 |
Serine Endopeptidases/*physiology | 4 | 21.0 |
Atrial Natriuretic Factor/physiology | 3 | 33.0 |
Nitric Oxide/physiology | 4 | 8.0 |
Cyclosporine/therapeutic use | 3 | 4.0 |
Delayed-Action Preparations | 6 | 5.0 |
*Echocardiography | 3 | 14.0 |
Heart Ventricles | 7 | 12.0 |
Nifedipine/administration & dosage/adverse effects/*therapeutic use | 2 | 100.0 |
DNA Mutational Analysis | 7 | 0.0 |
Glucose Clamp Technique | 6 | 5.0 |
Mass Screening | 2 | 1.0 |
Renin-Angiotensin System/genetics | 13 | 56.0 |
Stress, Psychological/physiopathology | 2 | 16.0 |
Angiotensin-Converting Enzyme Inhibitors/*administration & dosage | 14 | 93.0 |
Blood Pressure Monitoring, Ambulatory | 10 | 23.0 |
Lisinopril/*administration & dosage | 3 | 75.0 |
Captopril/*adverse effects | 9 | 90.0 |
Enalapril/*adverse effects | 10 | 90.0 |
Kidney Failure/*chemically induced | 2 | 100.0 |
Diabetic Nephropathies/drug therapy/genetics | 2 | 100.0 |
Hypertension/complications/drug therapy | 7 | 50.0 |
Antihypertensive Agents/adverse effects | 2 | 50.0 |
Imidazoles/adverse effects | 2 | 50.0 |
Patient Compliance | 7 | 4.0 |
*Thiophenes | 2 | 28.0 |
Kidney Failure/*drug therapy | 2 | 66.0 |
Myocardial Infarction/*drug therapy | 6 | 37.0 |
Renin-Angiotensin System/*drug effects | 27 | 20.0 |
Diabetic Nephropathies/*drug therapy | 4 | 50.0 |
Glomerular Filtration Rate/drug effects | 20 | 40.0 |
Hypertension/complications/*drug therapy/physiopathology | 6 | 54.0 |
Kidney/*drug effects/physiopathology | 9 | 69.0 |
Losartan/pharmacology | 5 | 15.0 |
Therapeutic Equivalency | 5 | 21.0 |
Angiotensin-Converting Enzyme Inhibitors/pharmacology/*therapeutic use | 24 | 82.0 |
Coronary Disease/blood/*drug therapy | 2 | 25.0 |
Hypertension/blood/*drug therapy | 14 | 66.0 |
Alzheimer Disease/*metabolism/pathology | 2 | 2.0 |
Peptidyl-Dipeptidase A/analysis/*metabolism | 3 | 100.0 |
Renin-Angiotensin System | 4 | 19.0 |
Binding Sites | 24 | 0.0 |
COS Cells | 3 | 0.0 |
Catalysis | 3 | 0.0 |
Catalytic Domain | 5 | 1.0 |
Enzyme Activation | 5 | 0.0 |
Molecular Sequence Data | 98 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
Sequence Homology, Amino Acid | 14 | 0.0 |
Sodium Chloride/pharmacology | 4 | 5.0 |
Genetic Predisposition to Disease/genetics | 4 | 0.0 |
Genetics, Population | 8 | 2.0 |
Rural Population | 4 | 4.0 |
Arteries/*enzymology | 2 | 50.0 |
Hypertension/*metabolism | 2 | 6.0 |
Tetrazoles/administration & dosage/*therapeutic use | 2 | 50.0 |
Blood Pressure/drug effects/*physiology | 6 | 85.0 |
Combined Modality Therapy | 11 | 0.0 |
Sympathetic Nervous System/drug effects | 2 | 50.0 |
Half-Life | 16 | 2.0 |
Kinins/metabolism | 3 | 60.0 |
Metalloendopeptidases/blood | 2 | 28.0 |
Peptidyl-Dipeptidase A/metabolism | 37 | 86.0 |
Cardiovascular Diseases/enzymology | 2 | 50.0 |
Peptidyl-Dipeptidase A/*blood/*genetics | 14 | 87.0 |
Proteinuria/drug therapy | 4 | 30.0 |
Angiotensin-Converting Enzyme Inhibitors/*pharmacology/*therapeutic use | 3 | 100.0 |
Clinical Trials/statistics & numerical data | 2 | 14.0 |
Myocardial Infarction/*drug therapy/prevention & control | 3 | 100.0 |
Endothelium, Vascular/*drug effects/metabolism | 2 | 3.0 |
Cardiology | 2 | 50.0 |
Digitalis Glycosides/therapeutic use | 3 | 100.0 |
Health Surveys | 2 | 2.0 |
Blood Pressure/*physiology | 16 | 17.0 |
Peptidyl-Dipeptidase A/chemistry/*physiology | 2 | 100.0 |
Administration, Oral | 32 | 3.0 |
Antihypertensive Agents/*administration & dosage | 8 | 47.0 |
Captopril/*administration & dosage | 3 | 100.0 |
Fosinopril/*administration & dosage | 3 | 100.0 |
Hypertension/complications | 8 | 13.0 |
*Genetics, Population | 2 | 0.0 |
Mutagenesis, Site-Directed | 9 | 0.0 |
Carotid Arteries/*pathology/ultrasonography | 2 | 14.0 |
Japan/epidemiology | 8 | 2.0 |
Protein Isoforms | 2 | 0.0 |
Kidney Failure, Chronic/etiology/genetics | 2 | 33.0 |
Lisinopril/*pharmacology/therapeutic use | 2 | 100.0 |
Sympathetic Nervous System/drug effects/physiopathology | 2 | 50.0 |
Blood Flow Velocity/drug effects/physiology | 2 | 40.0 |
Coronary Angiography | 13 | 5.0 |
Echocardiography, Doppler | 6 | 17.0 |
Enalapril/*pharmacology | 21 | 72.0 |
Heart Catheterization | 7 | 10.0 |
Hemodynamic Processes/drug effects/physiology | 14 | 58.0 |
*Estrogen Replacement Therapy | 3 | 2.0 |
Creatine/blood | 2 | 16.0 |
African Continental Ancestry Group/genetics | 6 | 2.0 |
Chromosome Mapping | 5 | 0.0 |
Haplotypes/genetics | 5 | 0.0 |
Jamaica | 3 | 13.0 |
Linkage (Genetics) | 11 | 0.0 |
Linkage Disequilibrium | 6 | 0.0 |
*Quantitative Trait, Heritable | 2 | 4.0 |
Hypertension/*drug therapy/*physiopathology | 5 | 83.0 |
Benzimidazoles/pharmacology | 2 | 4.0 |
Tetrazoles/pharmacology | 9 | 23.0 |
Point Mutation | 8 | 0.0 |
Hypertension/*drug therapy/physiopathology/*ultrasonography | 2 | 100.0 |
Atrial Natriuretic Factor/*pharmacology | 3 | 12.0 |
Cardiac Output, Low/*physiopathology | 3 | 25.0 |
Nitroglycerin/therapeutic use | 3 | 50.0 |
Vasodilator Agents/therapeutic use | 9 | 37.0 |
Chi-Square Distribution | 16 | 2.0 |
Disease Susceptibility | 4 | 0.0 |
Matched-Pair Analysis | 2 | 2.0 |
Taiwan | 3 | 1.0 |
Disease-Free Survival | 5 | 0.0 |
Diuretics/*therapeutic use | 8 | 44.0 |
Long-Term Care | 7 | 13.0 |
Survival Rate | 30 | 1.0 |
Sweden/epidemiology | 2 | 1.0 |
Blood Glucose/analysis | 8 | 1.0 |
Coronary Disease/*complications | 3 | 42.0 |
Heart Diseases/*prevention & control | 2 | 50.0 |
Heart Rate | 6 | 2.0 |
Hypertension/*complications/*drug therapy/physiopathology | 2 | 100.0 |
Nifedipine/*therapeutic use | 5 | 35.0 |
Vasodilator Agents/*therapeutic use | 3 | 10.0 |
Endothelium, Vascular/physiopathology | 4 | 11.0 |
Fibrosis | 6 | 4.0 |
Myocardium/pathology | 10 | 10.0 |
*Alu Elements | 3 | 17.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
Liposomes | 2 | 0.0 |
Mesocricetus | 3 | 1.0 |
Vasoactive Intestinal Peptide/*pharmacology | 2 | 2.0 |
Electrocardiography | 13 | 3.0 |
Primary Health Care/*standards | 3 | 50.0 |
*Women's Health | 2 | 6.0 |
*Polymorphism, Restriction Fragment Length | 3 | 0.0 |
*Plants, Medicinal | 3 | 4.0 |
Plasminogen Activator Inhibitor 1/*blood/*genetics | 4 | 66.0 |
Blood Pressure/*genetics | 9 | 16.0 |
Body Mass Index | 15 | 1.0 |
Linkage (Genetics)/*genetics | 3 | 1.0 |
Linkage Disequilibrium/genetics | 3 | 1.0 |
Lod Score | 3 | 0.0 |
Models, Genetic | 4 | 0.0 |
Nigeria | 2 | 3.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Apolipoproteins E/*genetics | 9 | 1.0 |
DNA/blood | 6 | 3.0 |
France | 5 | 1.0 |
Geography | 2 | 3.0 |
Longevity/*genetics | 3 | 8.0 |
Lymphocytes | 3 | 1.0 |
Amino Acid Substitution | 2 | 0.0 |
Peptidyl-Dipeptidase A/*chemistry/genetics/*metabolism | 3 | 100.0 |
*Point Mutation | 4 | 0.0 |
Protease Inhibitors/pharmacology | 7 | 3.0 |
Thiophenes/pharmacology | 2 | 5.0 |
Diabetes Complications | 9 | 6.0 |
Diabetes Mellitus/*drug therapy | 2 | 18.0 |
Hypertension/*drug therapy/etiology | 8 | 80.0 |
Bradykinin/pharmacology | 5 | 10.0 |
Enalaprilat/pharmacology | 7 | 70.0 |
Oligopeptides/pharmacology | 5 | 2.0 |
Serine Endopeptidases/metabolism | 5 | 4.0 |
Vascular Resistance | 7 | 12.0 |
Electrophoresis, Agar Gel | 4 | 0.0 |
Korea | 3 | 1.0 |
Lipids/blood | 13 | 2.0 |
Renin-Angiotensin System/*genetics/physiology | 4 | 44.0 |
Anti-Arrhythmia Agents/therapeutic use | 4 | 30.0 |
Cardiovascular Agents/*therapeutic use | 6 | 85.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | 4 | 12.0 |
Platelet Aggregation Inhibitors/therapeutic use | 5 | 17.0 |
Chromatography, High Pressure Liquid/*methods | 3 | 2.0 |
Oligopeptides/chemistry | 4 | 17.0 |
Hypertension/*therapy | 5 | 71.0 |
Peptidyl-Dipeptidase A/metabolism/physiology | 3 | 100.0 |
Endothelin-1/metabolism | 2 | 10.0 |
Immunoenzyme Techniques | 8 | 0.0 |
Stress, Mechanical | 5 | 1.0 |
1-Methyl-4-phenylpyridinium/pharmacology | 2 | 25.0 |
Hydroxyl Radical/*metabolism | 2 | 22.0 |
Bradykinin/diagnostic use | 2 | 100.0 |
Bronchial Provocation Tests | 3 | 4.0 |
Skin Tests | 2 | 1.0 |
*Food | 2 | 2.0 |
Blood Glucose/metabolism | 10 | 1.0 |
Blood Pressure/physiology | 19 | 11.0 |
Body Weight/drug effects | 7 | 3.0 |
Cholesterol/blood | 16 | 1.0 |
Collagen/metabolism | 6 | 2.0 |
Insulin/blood | 7 | 1.0 |
Organ Size/drug effects | 3 | 3.0 |
Triglycerides/blood | 12 | 0.0 |
DNA/*genetics | 3 | 0.0 |
Peptidyl-Dipeptidase A/drug effects/*metabolism | 2 | 100.0 |
Potassium Chloride/pharmacology | 3 | 5.0 |
Rats, Sprague-Dawley | 19 | 0.0 |
Species Specificity | 27 | 0.0 |
Lung/*metabolism | 2 | 2.0 |
Vasoconstriction/physiology | 3 | 23.0 |
Vasodilation/physiology | 4 | 13.0 |
Vasoconstriction/*drug effects | 4 | 11.0 |
Angiotensin-Converting Enzyme Inhibitors/*chemistry | 2 | 100.0 |
Antihypertensive Agents/*chemistry | 2 | 100.0 |
Brazil | 3 | 1.0 |
Enalapril/administration & dosage | 2 | 50.0 |
Exercise Tolerance/*drug effects | 3 | 100.0 |
Heart Failure, Congestive/*drug therapy/*physiopathology | 2 | 66.0 |
Hemodynamic Processes | 15 | 7.0 |
Lisinopril/administration & dosage | 3 | 100.0 |
Vasodilator Agents/pharmacology/therapeutic use | 3 | 75.0 |
Adrenal Cortex Hormones/*therapeutic use | 2 | 8.0 |
Fish Oils/therapeutic use | 2 | 40.0 |
Immunosuppressive Agents/*therapeutic use | 2 | 1.0 |
Kidney/*physiology | 2 | 4.0 |
Kidney Cortex/enzymology | 5 | 35.0 |
Blotting, Western | 13 | 0.0 |
Chromatography, DEAE-Cellulose | 2 | 3.0 |
Chromatography, Gel | 6 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 10 | 0.0 |
Organ Culture Techniques | 2 | 0.0 |
Kidney/pathology | 3 | 2.0 |
DNA Primers/chemistry | 9 | 0.0 |
Isoenzymes/genetics/metabolism | 2 | 1.0 |
Peptidyl-Dipeptidase A/genetics/*metabolism | 7 | 63.0 |
Reverse Transcriptase Polymerase Chain Reaction | 10 | 0.0 |
Angiotensin-Converting Enzyme Inhibitors/blood | 2 | 66.0 |
Drug Stability | 3 | 1.0 |
Quality Control | 2 | 1.0 |
Spectrum Analysis, Mass/*methods | 2 | 5.0 |
Biological Markers | 6 | 0.0 |
Coronary Artery Bypass | 4 | 7.0 |
Microscopy, Electron | 7 | 0.0 |
Myocardium/*pathology | 8 | 20.0 |
Peptidyl-Dipeptidase A/analysis | 8 | 80.0 |
Radionuclide Ventriculography | 5 | 62.0 |
Embryonic and Fetal Development/drug effects | 4 | 19.0 |
Maternal-Fetal Exchange | 3 | 2.0 |
Practice Guidelines | 9 | 11.0 |
Myocardial Infarction/*genetics | 11 | 28.0 |
Age of Onset | 12 | 0.0 |
Angiotensin II/genetics/metabolism | 2 | 100.0 |
Lipoproteins, HDL/blood | 2 | 0.0 |
Myocardial Infarction/blood/*genetics | 3 | 23.0 |
Cricetulus | 2 | 0.0 |
Neprilysin/*metabolism | 3 | 21.0 |
Peptide Fragments/metabolism | 3 | 0.0 |
*Genotype | 5 | 2.0 |
Cardiovascular Diseases/epidemiology | 4 | 14.0 |
Comorbidity | 9 | 3.0 |
Diabetes Mellitus/epidemiology | 4 | 12.0 |
Obesity/epidemiology | 3 | 12.0 |
Smoking/epidemiology | 6 | 9.0 |
Hypercholesterolemia/*therapy | 2 | 50.0 |
Losartan/*therapeutic use | 8 | 80.0 |
Biological Markers/blood | 17 | 1.0 |
C-Reactive Protein/metabolism | 2 | 0.0 |
Interleukin-6/blood | 2 | 0.0 |
Chromosomes, Human, Pair 17 | 4 | 1.0 |
Hypertension/*drug therapy/genetics | 3 | 100.0 |
Pregnancy Trimester, First | 3 | 1.0 |
Receptors, Angiotensin/*genetics/physiology | 2 | 100.0 |
Adrenergic beta-Antagonists/administration & dosage | 2 | 25.0 |
Calcium Channel Blockers/administration & dosage | 2 | 50.0 |
Diabetic Angiopathies/prevention & control | 2 | 66.0 |
Myocardial Infarction/etiology/*prevention & control | 2 | 100.0 |
Sweden | 3 | 1.0 |
Heart Rate/*drug effects | 4 | 13.0 |
Myocardial Infarction/drug therapy/*physiopathology | 4 | 66.0 |
Norepinephrine/blood | 13 | 6.0 |
Oxygen Consumption/drug effects | 3 | 7.0 |
Sympathetic Nervous System/*drug effects | 4 | 26.0 |
Angiotensin-Converting Enzyme Inhibitors/metabolism/pharmacology | 3 | 100.0 |
Captopril/metabolism/pharmacology | 2 | 66.0 |
Drug Tolerance | 6 | 5.0 |
Fosinopril/*therapeutic use | 5 | 100.0 |
Antihypertensive Agents/chemistry/*therapeutic use | 2 | 100.0 |
Renal Dialysis/*adverse effects | 3 | 2.0 |
Adrenergic beta-Antagonists/pharmacology/*therapeutic use | 4 | 80.0 |
Diuretics/administration & dosage | 3 | 75.0 |
Heart Failure, Congestive/*drug therapy/mortality | 5 | 100.0 |
DNA/analysis | 14 | 1.0 |
Leukocytes/chemistry | 2 | 4.0 |
Enzyme Induction | 5 | 0.0 |
Germany | 3 | 0.0 |
Peptidyl-Dipeptidase A/blood/*metabolism | 8 | 100.0 |
Cardiovascular Diseases/prevention & control | 3 | 23.0 |
Kidney Failure, Chronic/prevention & control | 2 | 100.0 |
Gene Therapy | 2 | 0.0 |
Hypertension/therapy | 2 | 66.0 |
Benzimidazoles/therapeutic use | 3 | 75.0 |
Diabetic Nephropathies/drug therapy | 3 | 60.0 |
Cardiovascular Diseases/*drug therapy/physiopathology | 3 | 75.0 |
Pyridines/*therapeutic use | 2 | 13.0 |
Thiazepines/*therapeutic use | 2 | 100.0 |
Biopsy | 8 | 0.0 |
Sarcoidosis/complications/*diagnosis | 2 | 100.0 |
*Genetic Predisposition to Disease | 7 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Angiotensin I/*metabolism | 7 | 77.0 |
Gene Duplication | 2 | 1.0 |
Gene Expression Regulation, Enzymologic | 9 | 1.0 |
Gene Library | 2 | 0.0 |
Kidney/*enzymology | 8 | 10.0 |
*Renin-Angiotensin System | 10 | 35.0 |
Sequence Alignment | 5 | 0.0 |
Cognition/*physiology | 3 | 4.0 |
Neuropsychological Tests | 2 | 0.0 |
Diabetes Mellitus, Type 2/*genetics | 3 | 1.0 |
Diabetic Nephropathies/enzymology/*genetics | 2 | 28.0 |
Hypertrophy, Left Ventricular/etiology/*genetics | 2 | 100.0 |
RNA, Messenger/analysis | 7 | 0.0 |
Heart Failure, Congestive/etiology/*prevention & control | 2 | 100.0 |
Indoles/*therapeutic use | 17 | 12.0 |
Myocardial Infarction/*complications | 3 | 50.0 |
Endothelium, Vascular/*drug effects/enzymology | 2 | 66.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Peptidyl-Dipeptidase A/*biosynthesis | 8 | 88.0 |
Angiotensin I/blood | 14 | 82.0 |
Statistics, Nonparametric | 2 | 0.0 |
Endothelium/enzymology | 10 | 50.0 |
Myocardial Infarction/*pathology | 2 | 40.0 |
Nitric-Oxide Synthase/genetics | 2 | 5.0 |
Heart Diseases/*etiology | 2 | 50.0 |
Kidney Failure, Chronic/*complications | 2 | 5.0 |
Bradykinin/metabolism | 8 | 57.0 |
Diabetic Nephropathies/*genetics/physiopathology | 2 | 50.0 |
Diabetic Retinopathy/genetics | 2 | 33.0 |
Nuclear Family | 2 | 0.0 |
Chlorides/pharmacology | 8 | 23.0 |
Chromosome Mapping/*methods | 2 | 1.0 |
Computer Simulation | 2 | 0.0 |
Pedigree | 6 | 0.0 |
Calcium/metabolism | 5 | 0.0 |
Enzyme Stability | 2 | 1.0 |
Pertussis Toxin | 2 | 1.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Angiotensin II/*pharmacology | 7 | 6.0 |
Blood Flow Velocity | 4 | 4.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Forearm/blood supply | 10 | 20.0 |
Plethysmography | 5 | 15.0 |
Angiotensin II/*biosynthesis | 10 | 66.0 |
Chromatography, Affinity | 5 | 0.0 |
Myocardial Contraction/drug effects | 5 | 12.0 |
Observer Variation | 2 | 1.0 |
Occupational Exposure/*adverse effects | 2 | 2.0 |
Scleroderma, Systemic/*complications | 3 | 50.0 |
*African Continental Ancestry Group | 3 | 2.0 |
Angiotensinogen/genetics | 11 | 33.0 |
Peptidyl-Dipeptidase A/blood/genetics | 3 | 100.0 |
Running | 2 | 5.0 |
Hypertension/complications/*enzymology | 2 | 66.0 |
Parents | 3 | 4.0 |
Lipids/*blood | 9 | 1.0 |
England | 2 | 1.0 |
Family Practice | 4 | 13.0 |
Cell Differentiation | 4 | 0.0 |
Epoprostenol/biosynthesis | 2 | 20.0 |
Interleukin-1/metabolism | 2 | 0.0 |
von Willebrand Factor/metabolism | 3 | 1.0 |
Aging/*genetics | 2 | 3.0 |
Oligopeptides/*chemistry | 2 | 13.0 |
Spectrometry, Fluorescence | 4 | 0.0 |
Educational Status | 2 | 3.0 |
Myocardial Contraction/*drug effects | 2 | 8.0 |
Antihypertensive Agents/pharmacology | 10 | 20.0 |
Hypertension/drug therapy/etiology | 2 | 40.0 |
Linear Models | 3 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Circadian Rhythm/*physiology | 2 | 2.0 |
Epinephrine/blood | 5 | 4.0 |
Heart Rate/drug effects/physiology | 2 | 11.0 |
*Imidazolidines | 6 | 31.0 |
Single-Blind Method | 11 | 4.0 |
Introns | 9 | 0.0 |
Saudi Arabia/epidemiology | 2 | 11.0 |
Hypertension/complications/*drug therapy | 13 | 11.0 |
Indoles/blood/*therapeutic use | 3 | 75.0 |
Placebos | 6 | 2.0 |
Molecular Weight | 14 | 0.0 |
European Continental Ancestry Group | 13 | 2.0 |
France/epidemiology | 5 | 3.0 |
Receptors, Angiotensin/blood/genetics | 2 | 100.0 |
Angiotensin II/*analysis | 3 | 75.0 |
Coronary Vessels/pathology | 2 | 4.0 |
Heart Failure, Congestive/*prevention & control | 2 | 66.0 |
Renin/*blood | 16 | 17.0 |
Chlorides/metabolism | 3 | 3.0 |
Aorta/enzymology | 3 | 100.0 |
Homeostasis | 5 | 1.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Mice, Knockout | 2 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Bradykinin/physiology | 3 | 60.0 |
Glucose/*metabolism | 3 | 1.0 |
Chromosome Deletion | 2 | 0.0 |
Aldosterone/physiology | 3 | 50.0 |
Ramipril/administration & dosage | 2 | 100.0 |
Cough/*chemically induced/epidemiology | 4 | 100.0 |
Safety | 2 | 1.0 |
*Tetrazoles | 4 | 57.0 |
Angiotensin I/genetics | 2 | 66.0 |
Angiotensin II/genetics | 2 | 50.0 |
DNA/*analysis | 4 | 1.0 |
Aldosterone/metabolism | 7 | 35.0 |
Heart Failure, Congestive/*drug therapy/metabolism | 3 | 60.0 |
Renin/*metabolism | 3 | 37.0 |
Sodium/*urine | 2 | 14.0 |
Diabetic Nephropathies/*enzymology | 2 | 100.0 |
Electrolytes/blood | 2 | 14.0 |
Confidence Intervals | 6 | 1.0 |
Chromatography, Ion Exchange | 6 | 1.0 |
Trypsin | 3 | 1.0 |
Stroke Volume | 5 | 8.0 |
DNA/chemistry | 2 | 0.0 |
DNA Transposable Elements/genetics | 5 | 12.0 |
Angiotensin-Converting Enzyme Inhibitors/metabolism | 3 | 100.0 |
Dipeptides/metabolism | 3 | 23.0 |
Iodine Radioisotopes | 3 | 0.0 |
Stromal Cells/enzymology | 2 | 18.0 |
Synovial Membrane/*enzymology | 2 | 50.0 |
Benzazepines/administration & dosage/*pharmacokinetics | 2 | 100.0 |
Biological Availability | 13 | 4.0 |
Infusions, Intravenous | 15 | 2.0 |
Gestational Age | 3 | 0.0 |
Electrophysiology | 2 | 0.0 |
Homeostasis/physiology | 3 | 5.0 |
Oligonucleotides, Antisense/*pharmacology | 2 | 2.0 |
Rats, Inbred WKY | 8 | 10.0 |
Renal Circulation | 4 | 11.0 |
Retroviridae/genetics | 2 | 0.0 |
Angiotensins/blood | 3 | 75.0 |
Bradykinin/blood | 8 | 72.0 |
Coronary Circulation | 2 | 8.0 |
Vascular Resistance/drug effects | 16 | 24.0 |
Indoles/adverse effects/*therapeutic use | 2 | 28.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
Genetic Screening | 3 | 0.0 |
Cold | 4 | 3.0 |
*Drug Utilization | 2 | 100.0 |
Hypertension/*drug therapy/epidemiology | 2 | 66.0 |
Italy | 7 | 1.0 |
Adrenergic beta-Antagonists/adverse effects/*therapeutic use | 3 | 100.0 |
Heart Failure, Congestive/*drug therapy/etiology/physiopathology | 2 | 100.0 |
Myocardial Infarction/complications | 4 | 33.0 |
Myocardial Reperfusion | 2 | 11.0 |
*Quality of Health Care | 3 | 12.0 |
Angiotensin II/*blood | 8 | 30.0 |
Hypertension/*blood/drug therapy | 4 | 26.0 |
Radioimmunoassay/*methods | 3 | 4.0 |
Diet | 5 | 1.0 |
Insulin Resistance/*physiology | 3 | 4.0 |
Captopril/administration & dosage | 3 | 50.0 |
Chickens | 2 | 0.0 |
Injections, Intravenous | 9 | 1.0 |
Glomerulonephritis/*drug therapy/physiopathology | 2 | 100.0 |
Proteinuria/physiopathology | 2 | 25.0 |
Lipoproteins/blood | 3 | 0.0 |
Plasminogen Activator Inhibitor 1/blood | 2 | 1.0 |
Tissue Plasminogen Activator/blood | 3 | 2.0 |
Angioneurotic Edema/*chemically induced/diagnosis | 2 | 100.0 |
Nitric-Oxide Synthase/*genetics | 4 | 4.0 |
Apolipoproteins B/*genetics | 6 | 3.0 |
Europe/epidemiology | 3 | 3.0 |
Gene Frequency/*genetics | 4 | 2.0 |
Cytokines/*blood | 2 | 0.0 |
Neopterin/blood | 2 | 7.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Aging/metabolism | 5 | 3.0 |
Embryonic and Fetal Development/physiology | 2 | 2.0 |
Fetus/metabolism/physiology | 2 | 40.0 |
Germ Cells/*enzymology | 2 | 50.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Spermatogenesis/physiology | 3 | 10.0 |
Testicular Neoplasms/*enzymology/pathology | 3 | 75.0 |
Testis/embryology/enzymology/growth & development | 2 | 100.0 |
Brain Ischemia/enzymology/*genetics | 2 | 50.0 |
Myocardial Ischemia/enzymology/*genetics | 2 | 66.0 |
Peptidyl-Dipeptidase A/*genetics/*metabolism | 5 | 100.0 |
Bradykinin/*blood | 3 | 75.0 |
Hypertension/*blood | 3 | 4.0 |
Lupus Erythematosus, Systemic/*enzymology/*genetics | 2 | 66.0 |
Angiotensin-Converting Enzyme Inhibitors/*economics/*therapeutic use | 3 | 100.0 |
Cost-Benefit Analysis | 8 | 7.0 |
Costs and Cost Analysis | 3 | 4.0 |
Health Care Costs | 3 | 11.0 |
Binding, Competitive | 4 | 0.0 |
Lung/*enzymology | 9 | 14.0 |
Macaca fascicularis | 6 | 2.0 |
Ramipril/analogs & derivatives/pharmacology | 2 | 100.0 |
Swine | 13 | 0.0 |
Cattle | 17 | 0.0 |
Immunoblotting | 2 | 0.0 |
beta 2-Microglobulin/metabolism | 2 | 2.0 |
Hemodynamic Processes/*drug effects | 38 | 34.0 |
DNA Transposable Elements/*genetics | 3 | 18.0 |
Hypertension/blood/*genetics | 3 | 25.0 |
Minisatellite Repeats | 3 | 2.0 |
Antibodies, Monoclonal | 7 | 0.0 |
Lipoproteins, LDL/blood/*isolation & purification | 2 | 66.0 |
Genetic Markers/genetics | 3 | 0.0 |
Membrane Proteins/genetics | 5 | 1.0 |
Mutation/*genetics | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Diabetes Mellitus, Type 1/complications/*genetics | 2 | 20.0 |
Diabetic Angiopathies/*genetics | 2 | 20.0 |
Diabetic Nephropathies/genetics | 3 | 42.0 |
Myocardial Ischemia/complications/genetics | 2 | 100.0 |
*Patient Compliance | 2 | 4.0 |
Coronary Disease/*drug therapy | 3 | 18.0 |
Myocardial Infarction/prevention & control | 2 | 25.0 |
Nitrates/*therapeutic use | 2 | 66.0 |
Vasoconstrictor Agents/administration & dosage | 2 | 33.0 |
Coronary Care Units | 3 | 50.0 |
Blood Pressure/*drug effects/physiology | 3 | 23.0 |
Homocysteine/*blood | 2 | 0.0 |
Cardiovascular Diseases/*genetics | 3 | 15.0 |
DNA Probes | 2 | 0.0 |
DNA Primers | 14 | 0.0 |
Homeostasis/drug effects/physiology | 2 | 33.0 |
Anticoagulants/therapeutic use | 6 | 8.0 |
Digoxin/*therapeutic use | 3 | 100.0 |
Drug Utilization/statistics & numerical data | 2 | 100.0 |
Medical Records | 3 | 4.0 |
Warfarin/therapeutic use | 2 | 6.0 |
Kidney/radionuclide imaging | 2 | 40.0 |
Controlled Clinical Trials | 3 | 13.0 |
Hypertension/*physiopathology | 9 | 14.0 |
Kidney Diseases/*prevention & control | 3 | 60.0 |
Angiotensinogen/metabolism | 2 | 40.0 |
Renal Circulation/drug effects | 17 | 53.0 |
Vasodilation/drug effects | 9 | 16.0 |
Endothelium, Vascular/*drug effects | 2 | 3.0 |
Infusions, Intra-Arterial | 3 | 4.0 |
Adsorption | 2 | 1.0 |
Kidney Diseases/prevention & control | 3 | 100.0 |
Ventricular Dysfunction, Left/drug therapy | 2 | 100.0 |
Myocardial Contraction/physiology | 3 | 25.0 |
Peptidyl-Dipeptidase A/physiology | 11 | 73.0 |
Cardiomyopathy, Dilated/*complications | 2 | 100.0 |
Myocardial Ischemia/*complications | 2 | 100.0 |
Kidney/*pathology | 3 | 5.0 |
Sclerosis | 2 | 3.0 |
Edetic Acid/pharmacology | 5 | 2.0 |
Guinea Pigs | 18 | 2.0 |
Peptides/metabolism | 2 | 0.0 |
Plasminogen Activator Inhibitor 1/genetics | 2 | 6.0 |
Anti-Inflammatory Agents/therapeutic use | 2 | 2.0 |
Hypertension/etiology | 2 | 4.0 |
Proteinuria/etiology | 2 | 6.0 |
Captopril/administration & dosage/*therapeutic use | 4 | 80.0 |
Aldosterone/*blood | 8 | 17.0 |
Captopril/therapeutic use | 15 | 78.0 |
Enalapril/therapeutic use | 17 | 85.0 |
Fosinopril/therapeutic use | 2 | 66.0 |
Indoles/therapeutic use | 8 | 40.0 |
Perindopril | 32 | 96.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Smoking/*adverse effects | 2 | 0.0 |
Atrial Natriuretic Factor/blood | 7 | 8.0 |
Fibrinolysis/*drug effects/physiology | 2 | 28.0 |
Hemodynamic Processes/*drug effects/physiology | 4 | 66.0 |
von Willebrand Factor/*analysis | 2 | 1.0 |
Blood Vessels/metabolism | 2 | 7.0 |
Myocardium/metabolism | 3 | 1.0 |
Coronary Disease/*therapy | 2 | 28.0 |
Evidence-Based Medicine | 4 | 12.0 |
*Practice Guidelines | 3 | 11.0 |
Coronary Disease/physiopathology | 3 | 18.0 |
*Heart Transplantation | 3 | 3.0 |
Diabetic Retinopathy/etiology/*genetics | 2 | 100.0 |
Clinical Protocols | 3 | 4.0 |
Heart Failure, Congestive/*therapy | 2 | 100.0 |
*Outcome and Process Assessment (Health Care) | 2 | 22.0 |
*Quality Assurance, Health Care | 2 | 9.0 |
Quality Indicators, Health Care | 2 | 100.0 |
Ventricular Dysfunction, Left/diagnosis | 2 | 66.0 |
Creatinine/metabolism | 9 | 12.0 |
Hypotension/*chemically induced | 3 | 42.0 |
Aldosterone/urine | 2 | 20.0 |
Peptidyl-Dipeptidase A/blood/drug effects | 2 | 100.0 |
*Albuminuria | 2 | 6.0 |
Diabetes Mellitus, Type 2/complications/*physiopathology/urine | 2 | 66.0 |
Glycine/chemistry | 2 | 6.0 |
Angiotensin II | 2 | 40.0 |
*Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Introns/*genetics | 2 | 1.0 |
*Transcription, Genetic | 3 | 0.0 |
Antihypertensive Agents/*adverse effects/therapeutic use | 7 | 87.0 |
*Insulin Resistance | 8 | 4.0 |
*Diet, Sodium-Restricted | 4 | 26.0 |
Hypertension/diet therapy/drug therapy/*therapy | 2 | 100.0 |
Indapamide/therapeutic use | 2 | 100.0 |
Guideline Adherence | 3 | 33.0 |
Heart Failure, Congestive/complications/drug therapy | 3 | 100.0 |
Hematocrit | 5 | 1.0 |
Diabetes Mellitus, Type 1/*drug therapy | 2 | 6.0 |
Hydrochlorothiazide/therapeutic use | 7 | 70.0 |
Anaphylaxis/*etiology | 2 | 28.0 |
Cell Fractionation | 2 | 0.0 |
Cardiac Output | 2 | 4.0 |
*Hemodynamic Processes | 2 | 4.0 |
Oxygen Consumption | 4 | 1.0 |
Ventricular Remodeling/*physiology | 2 | 22.0 |
Europe | 4 | 1.0 |
Angiotensin-Converting Enzyme Inhibitors/*pharmacokinetics | 7 | 100.0 |
Enalapril/*pharmacokinetics | 2 | 100.0 |
Inflammation | 3 | 0.0 |
Metabolic Clearance Rate | 4 | 1.0 |
Peptidyl-Dipeptidase A/*chemistry/*metabolism | 3 | 100.0 |
Mutation, Missense | 2 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Insulin Resistance/*genetics | 3 | 3.0 |
Enalapril/administration & dosage/*analogs & derivatives/pharmacology | 2 | 100.0 |
Kidney Failure, Chronic/*drug therapy/physiopathology | 5 | 100.0 |
*Signal Transduction | 2 | 0.0 |
Electrocardiography, Ambulatory | 4 | 13.0 |
Kidney Transplantation/*physiology | 2 | 4.0 |
*Renal Dialysis | 9 | 2.0 |
Blood Flow Velocity/drug effects | 2 | 9.0 |
*Death, Sudden, Cardiac | 3 | 33.0 |
Peptidyl-Dipeptidase A/blood/*drug effects | 4 | 100.0 |
*Randomized Controlled Trials | 2 | 10.0 |
Cilazapril/*therapeutic use | 4 | 100.0 |
*Quality of Life | 7 | 7.0 |
Kidney/*drug effects/metabolism | 2 | 18.0 |
Sodium/urine | 10 | 16.0 |
Tetrazoles/*pharmacology | 5 | 25.0 |
Ascorbic Acid/pharmacology | 2 | 3.0 |
Cardiac Output, Low/physiopathology | 2 | 66.0 |
Coronary Disease/physiopathology/therapy | 2 | 100.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
omega-N-Methylarginine/pharmacology | 2 | 4.0 |
Angiotensin II/pharmacology | 9 | 12.0 |
*Kidney Transplantation | 5 | 1.0 |
*Models, Genetic | 2 | 1.0 |
Hypertension/physiopathology/*prevention & control | 2 | 100.0 |
Antihypertensive Agents/pharmacokinetics/*therapeutic use | 3 | 100.0 |
Blood Pressure/drug effects/genetics | 2 | 50.0 |
Genome | 2 | 0.0 |
*Pharmacogenetics | 2 | 4.0 |
Asia | 2 | 2.0 |
Adrenal Cortex Hormones/therapeutic use | 7 | 10.0 |
Arrhythmia/*drug therapy | 2 | 18.0 |
Myocardial Infarction/genetics | 3 | 12.0 |
Kidney Diseases/*metabolism/pathology | 2 | 16.0 |
Signal Transduction | 4 | 0.0 |
*Cardiac Surgical Procedures | 4 | 8.0 |
Length of Stay | 3 | 3.0 |
Ventricular Dysfunction, Left/*drug therapy | 3 | 100.0 |
Tumor Cells, Cultured | 4 | 0.0 |
Enzyme Inhibitors/*pharmacology | 3 | 0.0 |
*Sequence Deletion | 7 | 1.0 |
Arteries/physiopathology | 2 | 20.0 |
Microcirculation/drug effects | 2 | 7.0 |
Hypertension/*complications/drug therapy | 5 | 55.0 |
Remission Induction | 2 | 0.0 |
Natriuresis/drug effects | 7 | 25.0 |
Angiotensin II/*biosynthesis/physiology | 2 | 100.0 |
Vasoconstriction | 2 | 11.0 |
Plasminogen Activator Inhibitor 1/*genetics | 2 | 5.0 |
Hypertrophy, Left Ventricular/*complications/physiopathology | 2 | 100.0 |
Kidney/*metabolism | 4 | 2.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Heart Transplantation | 4 | 10.0 |
Receptors, Angiotensin/*metabolism | 2 | 12.0 |
Angiotensin II/biosynthesis | 6 | 85.0 |
Angiotensinogen/biosynthesis | 2 | 100.0 |
Coronary Vessels/metabolism | 4 | 19.0 |
Indoles/pharmacology/*therapeutic use | 2 | 66.0 |
Myocardial Infarction/drug therapy | 6 | 75.0 |
*Emergencies | 2 | 33.0 |
Angioplasty, Balloon | 3 | 27.0 |
Finland/epidemiology | 2 | 1.0 |
Nephrectomy | 2 | 2.0 |
Northern Ireland/epidemiology | 2 | 13.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
Myocardial Infarction/enzymology/ethnology/*genetics | 2 | 100.0 |
Serine Endopeptidases/physiology | 3 | 33.0 |
Area Under Curve | 4 | 0.0 |
Serine Endopeptidases/genetics | 3 | 8.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Syndrome | 2 | 0.0 |
Kidney Transplantation/*adverse effects/pathology | 2 | 100.0 |
Lung/*physiopathology | 2 | 10.0 |
Apolipoproteins B/blood | 3 | 1.0 |
Calcium Channel Blockers/*administration & dosage | 4 | 80.0 |
Endothelium, Vascular/cytology/*metabolism | 3 | 1.0 |
Metoprolol/therapeutic use | 2 | 50.0 |
*Ventricular Function, Left | 3 | 23.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Proteinuria/*drug therapy | 6 | 100.0 |
*Blood Pressure/drug effects | 4 | 33.0 |
Myocardial Infarction/*drug therapy/physiopathology | 6 | 75.0 |
*Chromosome Deletion | 2 | 0.0 |
Glomerular Filtration Rate | 7 | 5.0 |
Aorta/*enzymology | 2 | 33.0 |
Mammals | 2 | 0.0 |
Myocardium/*enzymology | 6 | 7.0 |
Angiotensin I/*pharmacology | 5 | 83.0 |
Culture Media | 3 | 0.0 |
Imidazoles/pharmacology | 9 | 4.0 |
Sperm Capacitation | 2 | 15.0 |
Endothelium, Vascular/cytology/*enzymology | 2 | 9.0 |
Tetradecanoylphorbol Acetate/pharmacology | 5 | 0.0 |
Sports/*physiology | 3 | 20.0 |
Evolution, Molecular | 2 | 0.0 |
Carrier Proteins/*blood | 2 | 0.0 |
*Glycoproteins | 2 | 0.0 |
Hemoglobins/analysis | 3 | 1.0 |
Kidney Failure, Chronic/*blood/complications/therapy | 2 | 18.0 |
*Mutation | 3 | 0.0 |
Graft Survival | 2 | 0.0 |
E-Selectin/metabolism | 2 | 4.0 |
Lipoproteins, LDL/metabolism | 3 | 1.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Neurotransmitters/*blood | 2 | 25.0 |
Endothelins/*blood | 2 | 7.0 |
*Exercise | 7 | 5.0 |
Diabetic Nephropathies/complications | 2 | 33.0 |
Diabetic Retinopathy/*genetics | 2 | 20.0 |
HLA Antigens/genetics | 2 | 0.0 |
Diabetic Nephropathies/*genetics | 4 | 16.0 |
Glucose/metabolism | 3 | 1.0 |
Insulin/pharmacology | 2 | 0.0 |
Captopril/*pharmacology | 28 | 71.0 |
Lisinopril/*pharmacology | 3 | 50.0 |
*Cardiopulmonary Bypass | 2 | 2.0 |
Vascular Resistance/*drug effects | 3 | 23.0 |
Amine Oxidoreductases/*genetics | 4 | 1.0 |
Continental Population Groups | 5 | 2.0 |
Captopril/*adverse effects/therapeutic use | 2 | 100.0 |
Cough/*chemically induced | 12 | 92.0 |
Heart Transplantation/*physiology | 3 | 14.0 |
Blood Pressure/drug effects/physiology | 13 | 34.0 |
Natriuresis/*drug effects/physiology | 3 | 100.0 |
Catecholamines/*blood | 2 | 6.0 |
Calcium Channel Blockers/pharmacokinetics | 2 | 33.0 |
Hypertension/metabolism | 3 | 23.0 |
Potassium Channels/drug effects | 2 | 16.0 |
Vasodilation | 2 | 5.0 |
Cell Membrane/metabolism | 5 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Exons | 7 | 0.0 |
Endothelium, Vascular/cytology/enzymology | 2 | 22.0 |
Epithelial Cells/enzymology | 3 | 8.0 |
Fibroblasts/enzymology | 2 | 1.0 |
Sarcoidosis/*diagnosis/drug therapy/enzymology | 3 | 100.0 |
Steroids/therapeutic use | 2 | 5.0 |
Tomography, X-Ray Computed | 5 | 0.0 |
Myocardial Infarction/enzymology/epidemiology/*genetics | 2 | 66.0 |
Hydrochlorothiazide/*therapeutic use | 3 | 50.0 |
Hemodynamic Processes/physiology | 7 | 12.0 |
Renal Circulation/physiology | 2 | 15.0 |
Kidney Diseases/*drug therapy/physiopathology | 3 | 60.0 |
Probability | 5 | 0.0 |
Kidney/*drug effects/pathology | 3 | 37.0 |
*Blood Pressure Monitoring, Ambulatory | 2 | 11.0 |
Hypertension/*genetics/physiopathology | 4 | 16.0 |
Life Style | 3 | 2.0 |
Cardiomegaly/*genetics/physiopathology | 2 | 66.0 |
Hypertrophy, Left Ventricular/etiology | 3 | 75.0 |
Physical Fitness/*physiology | 2 | 5.0 |
Substance P/metabolism | 2 | 3.0 |
Databases, Factual | 2 | 0.0 |
Hypertension/*ethnology/*genetics | 2 | 50.0 |
Creatinine/urine | 3 | 2.0 |
Electrolytes/urine | 2 | 25.0 |
Uric Acid/urine | 2 | 33.0 |
Cardiovascular Diseases/drug therapy | 4 | 36.0 |
Cardiovascular Diseases/*drug therapy/metabolism | 2 | 66.0 |
Metalloendopeptidases/antagonists & inhibitors/metabolism | 2 | 66.0 |
Angiotensin-Converting Enzyme Inhibitors/blood/*pharmacokinetics/urine | 2 | 100.0 |
Endopeptidases/drug effects | 2 | 66.0 |
Diabetic Nephropathies/*prevention & control | 2 | 40.0 |
Drug Costs | 2 | 12.0 |
Kidney/drug effects | 21 | 45.0 |
Hypertension/complications/*drug therapy/*physiopathology | 2 | 66.0 |
Ventricular Dysfunction, Left/complications | 2 | 50.0 |
Renin/genetics | 2 | 16.0 |
Biphenyl Compounds/therapeutic use | 3 | 75.0 |
Diabetes Mellitus, Type 2/drug therapy/*physiopathology | 2 | 66.0 |
Plasminogen Activator Inhibitor 1/*blood | 2 | 6.0 |
Twins, Monozygotic | 2 | 2.0 |
*Tissue Donors | 2 | 1.0 |
Kidney/drug effects/*physiopathology | 2 | 33.0 |
Renal Plasma Flow/drug effects | 2 | 40.0 |
Dexamethasone/*therapeutic use | 2 | 11.0 |
Lung/embryology/*enzymology | 2 | 50.0 |
*Angioplasty, Balloon | 2 | 14.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 2 | 2.0 |
Glutathione/metabolism | 2 | 0.0 |
Oxidation-Reduction | 5 | 0.0 |
Heart Failure, Congestive/etiology | 2 | 28.0 |
Bradykinin/*metabolism | 2 | 50.0 |
Coronary Circulation/drug effects | 5 | 33.0 |
Energy Metabolism | 2 | 1.0 |
Hypertrophy, Left Ventricular/*drug therapy | 3 | 100.0 |
Enalapril/administration & dosage/pharmacology | 2 | 100.0 |
Coronary Disease/*physiopathology | 2 | 11.0 |
Drug Utilization | 2 | 18.0 |
Hong Kong | 2 | 4.0 |
Kallikreins/urine | 2 | 25.0 |
Oxygen Consumption/*drug effects | 2 | 25.0 |
Angiotensinogen/blood | 2 | 28.0 |
Blood Volume | 4 | 8.0 |
Epithelium/enzymology | 2 | 5.0 |
Insulin/*therapeutic use | 2 | 2.0 |
Hypertension/*drug therapy/enzymology | 3 | 60.0 |
Cholecystokinin/*metabolism | 2 | 11.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
Proteinuria/complications | 3 | 60.0 |
Bradykinin/*physiology | 3 | 75.0 |
Hypertension/drug therapy/metabolism | 3 | 50.0 |
Myocardial Ischemia/drug therapy | 4 | 100.0 |
Arrhythmia/prevention & control | 2 | 100.0 |
Cyclooxygenase Inhibitors/pharmacology | 3 | 4.0 |
Prostaglandins/physiology | 2 | 11.0 |
Heart/*drug effects | 5 | 12.0 |
Kininogens/blood | 2 | 66.0 |
Muscle, Smooth, Vascular/drug effects | 4 | 17.0 |
Up-Regulation | 2 | 0.0 |
Indoles/administration & dosage/*therapeutic use | 2 | 33.0 |
Serum Albumin/analysis | 3 | 1.0 |
Bronchoalveolar Lavage Fluid/*chemistry | 6 | 10.0 |
Histocytochemistry | 8 | 1.0 |
Lung Diseases/*enzymology | 8 | 88.0 |
*Exercise Test | 3 | 8.0 |
Hypertension, Renal/drug therapy/physiopathology | 4 | 100.0 |
Albuminuria/*drug therapy | 2 | 40.0 |
Diabetes Mellitus/*drug therapy/pathology | 2 | 100.0 |
Diabetic Nephropathies/prevention & control | 2 | 50.0 |
Apolipoproteins C/*genetics | 3 | 3.0 |
Coronary Disease/epidemiology | 2 | 10.0 |
Ethnic Groups/genetics | 3 | 1.0 |
Coronary Vessels/*enzymology/pathology | 2 | 100.0 |
Bradykinin/*pharmacology | 6 | 17.0 |
Angiotensins/*blood | 3 | 50.0 |
Fluorometry | 5 | 6.0 |
Oligopeptides/*pharmacology | 4 | 4.0 |
Molecular Structure | 6 | 0.0 |
Blood Pressure Determination | 3 | 17.0 |
Canada | 2 | 1.0 |
Enalapril/adverse effects/therapeutic use | 4 | 100.0 |
Muscles/*enzymology | 2 | 2.0 |
Serine Endopeptidases/*analysis | 2 | 16.0 |
Respiratory Function Tests | 9 | 5.0 |
Hypertrophy, Left Ventricular/genetics | 2 | 50.0 |
Receptor, Bradykinin B2/*genetics | 2 | 100.0 |
Angiotensin I/biosynthesis | 2 | 100.0 |
Fluorescent Antibody Technique | 10 | 0.0 |
Heart Failure, Congestive/*pathology | 2 | 40.0 |
Kidney/metabolism | 2 | 0.0 |
Liver/metabolism | 5 | 0.0 |
Pressoreceptors/drug effects | 3 | 50.0 |
Indoles/*pharmacology | 3 | 3.0 |
Anemia/*chemically induced | 2 | 40.0 |
Antihypertensive Agents/adverse effects/therapeutic use | 2 | 50.0 |
Seasons | 2 | 1.0 |
Bradykinin/*pharmacology/physiology | 2 | 100.0 |
Peptidyl-Dipeptidase A/*physiology | 5 | 62.0 |
Benzazepines/*therapeutic use | 6 | 60.0 |
Coronary Disease/enzymology/*genetics | 3 | 33.0 |
Hypertension/enzymology/*genetics | 9 | 64.0 |
Diastole/*genetics | 2 | 100.0 |
China | 5 | 1.0 |
Hypertension/epidemiology/*genetics | 2 | 10.0 |
Receptor, Angiotensin, Type 1/*genetics | 3 | 25.0 |
*Circadian Rhythm | 3 | 1.0 |
Peptide Fragments/blood | 3 | 2.0 |
Hypertrophy, Left Ventricular/*drug therapy/physiopathology | 2 | 100.0 |
Angiotensin II/biosynthesis/*physiology | 2 | 100.0 |
Cardiovascular System/enzymology | 2 | 66.0 |
Hypertension/*etiology | 2 | 9.0 |
Body Weight | 2 | 0.0 |
Imidazoles/*therapeutic use | 3 | 27.0 |
Cardiovascular Diseases/*drug therapy/*genetics | 2 | 66.0 |
Cell Division/drug effects | 2 | 0.0 |
Angiotensin-Converting Enzyme Inhibitors/*metabolism | 5 | 100.0 |
Muscle Contraction/drug effects | 3 | 3.0 |
Temperature | 3 | 0.0 |
Depression, Chemical | 4 | 2.0 |
Verapamil/therapeutic use | 2 | 40.0 |
Verapamil/*therapeutic use | 4 | 50.0 |
Primary Health Care | 2 | 14.0 |
Referral and Consultation | 2 | 11.0 |
Calcium Channel Blockers/administration & dosage/*therapeutic use | 2 | 100.0 |
Evaluation Studies | 3 | 0.0 |
*Gene Frequency | 5 | 0.0 |
Heart/physiopathology | 3 | 8.0 |
Arteriosclerosis/physiopathology | 2 | 9.0 |
Heart Failure, Congestive/drug therapy/physiopathology | 3 | 75.0 |
Tissue Plasminogen Activator/*blood | 2 | 6.0 |
Lithium/urine | 2 | 40.0 |
Renal Circulation/*drug effects | 10 | 41.0 |
Biphenyl Compounds/*adverse effects/therapeutic use | 2 | 100.0 |
Imidazoles/*adverse effects/therapeutic use | 2 | 100.0 |
Losartan | 21 | 55.0 |
Renal Dialysis | 14 | 4.0 |
Tetrazoles/*adverse effects/therapeutic use | 2 | 100.0 |
Cloning, Molecular | 10 | 0.0 |
*Peptides | 2 | 3.0 |
Hypotension/chemically induced | 6 | 46.0 |
Myocardial Infarction/enzymology/genetics | 3 | 60.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Angioplasty, Transluminal, Percutaneous Coronary | 6 | 12.0 |
Antihypertensive Agents/*adverse effects | 10 | 83.0 |
Receptor, Angiotensin, Type 2/*antagonists & inhibitors | 2 | 100.0 |
Tissue Distribution | 14 | 0.0 |
Indoles/*adverse effects/therapeutic use | 2 | 100.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Ventricular Function, Left/drug effects | 8 | 38.0 |
Hypertension/enzymology/ethnology/*genetics | 3 | 100.0 |
Captopril/adverse effects/*therapeutic use | 12 | 92.0 |
Enzyme Inhibitors/pharmacology/therapeutic use | 2 | 10.0 |
Hydrochlorothiazide/*administration & dosage | 3 | 75.0 |
Gene Expression Regulation, Enzymologic/physiology | 3 | 3.0 |
Kallikreins/metabolism | 4 | 26.0 |
Angioplasty | 2 | 33.0 |
Ramipril/pharmacology/*therapeutic use | 2 | 100.0 |
Hypertension/*drug therapy/pathology | 2 | 100.0 |
Myocardial Infarction/*drug therapy/mortality/physiopathology | 3 | 100.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 3 | 2.0 |
Renin-Angiotensin System/genetics/physiology | 3 | 60.0 |
Dinitrofluorobenzene/pharmacology | 2 | 50.0 |
Oligopeptides/metabolism | 6 | 10.0 |
Diabetic Nephropathies/*drug therapy/metabolism | 2 | 66.0 |
Substance P/*metabolism | 2 | 6.0 |
Enalapril/*administration & dosage | 6 | 100.0 |
Catecholamines/blood | 4 | 8.0 |
Fosinopril/*pharmacology | 2 | 100.0 |
Adrenergic alpha-Antagonists/*therapeutic use | 2 | 40.0 |
Indomethacin/pharmacology | 3 | 1.0 |
Pulse/drug effects | 3 | 15.0 |
Cardiac Output/drug effects | 4 | 13.0 |
Cilazapril/*pharmacology | 2 | 66.0 |
Peptidyl-Dipeptidase A/*blood/drug effects | 3 | 100.0 |
Captopril/metabolism | 3 | 75.0 |
Radioligand Assay | 3 | 0.0 |
Hypertension/drug therapy/*metabolism | 6 | 66.0 |
Lipids/metabolism | 2 | 0.0 |
Potassium/metabolism | 3 | 2.0 |
Enalapril/*adverse effects/therapeutic use | 2 | 66.0 |
Hypertension/physiopathology | 5 | 23.0 |
Kidney Failure, Chronic/*physiopathology | 2 | 13.0 |
Kidney/*drug effects | 8 | 33.0 |
Coronary Disease/complications | 3 | 21.0 |
Cardiopulmonary Bypass | 3 | 6.0 |
Phosphodiesterase Inhibitors/therapeutic use | 2 | 28.0 |
Glycosylation | 6 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Cardiomyopathy, Dilated/drug therapy | 2 | 100.0 |
New Zealand | 3 | 12.0 |
Random Allocation | 26 | 5.0 |
Aspirin/therapeutic use | 4 | 10.0 |
Myocardial Infarction/*therapy | 3 | 27.0 |
Hematopoiesis | 2 | 0.0 |
*Antihypertensive Agents | 2 | 66.0 |
Neprilysin | 9 | 12.0 |
Ireland | 2 | 3.0 |
Drug Design | 3 | 0.0 |
Cardiac Output, Low/drug therapy | 2 | 100.0 |
Heart/drug effects | 6 | 12.0 |
Peptidyl-Dipeptidase A/*analysis/genetics | 2 | 100.0 |
Aging/physiology | 4 | 2.0 |
Hypertension/*complications/drug therapy/physiopathology | 2 | 100.0 |
Myocardium/enzymology | 6 | 7.0 |
Isoquinolines/adverse effects/*therapeutic use | 2 | 66.0 |
Oligopeptides | 3 | 9.0 |
Microvilli/enzymology | 4 | 19.0 |
Prednisolone/therapeutic use | 2 | 2.0 |
Peptidyl-Dipeptidase A/*pharmacology | 2 | 100.0 |
Peptidyl-Dipeptidase A/*blood/genetics | 2 | 100.0 |
Indians, North American/*genetics | 2 | 2.0 |
Coronary Circulation/*drug effects | 2 | 14.0 |
Hypertrophy, Left Ventricular/drug therapy | 2 | 50.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Heart/*physiology | 5 | 8.0 |
Eye/*metabolism | 2 | 13.0 |
Gene Expression/*genetics | 2 | 1.0 |
Transcription, Genetic | 5 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Sarcoidosis, Pulmonary/*blood | 2 | 66.0 |
Cough/*chemically induced/metabolism | 2 | 100.0 |
Alanine/*analogs & derivatives/pharmacology | 2 | 40.0 |
Captopril/administration & dosage/*pharmacology | 5 | 71.0 |
Oligopeptides/*blood | 2 | 40.0 |
Potassium/blood | 9 | 10.0 |
Enalaprilat/blood | 2 | 100.0 |
Iodine Radioisotopes/diagnostic use | 6 | 1.0 |
Radioimmunoassay | 21 | 1.0 |
Tablets | 2 | 5.0 |
Enalapril/*analogs & derivatives/pharmacology/therapeutic use | 3 | 75.0 |
Posture | 9 | 9.0 |
Coronary Circulation/physiology | 2 | 22.0 |
Endothelium, Vascular/physiology | 2 | 3.0 |
Digitalis | 3 | 100.0 |
Albuminuria | 6 | 12.0 |
Electrocardiography/drug effects | 2 | 6.0 |
Hypertension/complications/*physiopathology | 2 | 25.0 |
Cardiac Volume/physiology | 2 | 100.0 |
*Peritoneal Dialysis | 2 | 3.0 |
Arteries/drug effects/*pathology/physiopathology | 2 | 100.0 |
Hypertension/*drug therapy/*pathology/physiopathology | 2 | 100.0 |
Cilazapril/adverse effects/*therapeutic use | 2 | 100.0 |
Regional Blood Flow/drug effects/physiology | 2 | 28.0 |
Exercise Test/*drug effects | 4 | 80.0 |
Animals, Newborn | 2 | 0.0 |
Models, Theoretical | 2 | 1.0 |
Cell Division | 4 | 0.0 |
Kinins/*metabolism | 3 | 50.0 |
Adrenergic beta-Antagonists/adverse effects | 3 | 100.0 |
Calcium Channel Blockers/adverse effects | 3 | 50.0 |
Carbohydrates/*metabolism | 2 | 5.0 |
Diuretics/adverse effects | 4 | 100.0 |
Lipids/*metabolism | 2 | 0.0 |
Proteinuria/*drug therapy/enzymology | 2 | 100.0 |
Aldosterone/*physiology | 2 | 22.0 |
Heart Failure, Congestive/drug therapy/*physiopathology | 3 | 33.0 |
Heart Failure, Congestive/pathology/*physiopathology | 2 | 100.0 |
Diastole/physiology | 2 | 15.0 |
Wound Healing/physiology | 2 | 3.0 |
Heart Failure, Congestive/drug therapy/mortality | 2 | 100.0 |
Heart Failure, Congestive/blood/*drug therapy | 2 | 33.0 |
Oligonucleotide Probes/genetics | 4 | 3.0 |
*Linkage (Genetics) | 2 | 0.0 |
*Angiotensin-Converting Enzyme Inhibitors | 47 | 92.0 |
Peptidyl-Dipeptidase A/*urine | 3 | 100.0 |
Coronary Disease/enzymology/epidemiology/*genetics | 2 | 40.0 |
Peptidyl-Dipeptidase A/biosynthesis/*genetics | 2 | 50.0 |
Atenolol/adverse effects/*therapeutic use | 2 | 100.0 |
Ramipril/adverse effects/*therapeutic use | 2 | 100.0 |
Cardiomegaly/physiopathology | 3 | 50.0 |
Hypertrophy | 2 | 1.0 |
Sarcoidosis/*diagnosis | 3 | 100.0 |
Hypertension/*drug therapy/metabolism/physiopathology | 6 | 66.0 |
Sodium/metabolism | 5 | 3.0 |
Biphenyl Compounds/pharmacology/*therapeutic use | 2 | 50.0 |
Imidazoles/pharmacology/*therapeutic use | 2 | 50.0 |
Tetrazoles/pharmacology/*therapeutic use | 2 | 40.0 |
Heart Failure, Congestive/*physiopathology | 6 | 30.0 |
Receptors, Adrenergic, beta/*physiology | 2 | 28.0 |
Blood Vessels/*drug effects | 2 | 50.0 |
Ventricular Function, Left/drug effects/physiology | 4 | 66.0 |
Ventricular Function, Left/*drug effects/physiology | 2 | 66.0 |
Biphenyl Compounds/*pharmacology | 4 | 26.0 |
Imidazoles/*pharmacology | 6 | 8.0 |
Hypertension/*drug therapy/physiopathology/psychology | 2 | 100.0 |
Hypercholesterolemia/complications | 2 | 16.0 |
Smoking/adverse effects | 3 | 1.0 |
Denmark | 3 | 1.0 |
Myocardial Contraction | 2 | 4.0 |
Antihypertensive Agents/*administration & dosage/adverse effects | 3 | 75.0 |
Calcium Channel Blockers/*administration & dosage/adverse effects | 2 | 100.0 |
Diabetic Nephropathies/*drug therapy/physiopathology | 3 | 100.0 |
Myocardial Infarction/*drug therapy/mortality | 3 | 100.0 |
Captopril/adverse effects/therapeutic use | 2 | 100.0 |
Coronary Disease/drug therapy | 3 | 23.0 |
Renin/*antagonists & inhibitors | 5 | 55.0 |
Diabetes Mellitus, Type 1/enzymology/*genetics/physiopathology | 2 | 100.0 |
Hypertrophy, Left Ventricular/enzymology/*genetics | 2 | 100.0 |
Netherlands/epidemiology | 3 | 2.0 |
Pregnancy Complications, Cardiovascular/drug therapy | 3 | 75.0 |
Amlodipine/therapeutic use | 3 | 50.0 |
*Myocardial Contraction | 2 | 5.0 |
Autoradiography | 4 | 0.0 |
Brain/*enzymology | 2 | 1.0 |
Enalapril/administration & dosage/*adverse effects | 4 | 100.0 |
Colorimetry | 3 | 5.0 |
Endomyocardial Fibrosis/pathology/physiopathology | 2 | 100.0 |
Peptides/physiology | 2 | 5.0 |
Hypertension/*pathology | 2 | 33.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
Myocardial Ischemia/*genetics | 2 | 20.0 |
Captopril/adverse effects | 6 | 85.0 |
Diastole/drug effects | 4 | 66.0 |
Systole/drug effects | 4 | 40.0 |
Myocardium/metabolism/*pathology | 2 | 10.0 |
Citric Acid | 3 | 8.0 |
Gallium Radioisotopes/diagnostic use | 3 | 33.0 |
Hypertension/complications/*drug therapy/metabolism | 3 | 100.0 |
Atenolol/*therapeutic use | 2 | 15.0 |
Semen/*enzymology | 4 | 20.0 |
Copper/pharmacology | 2 | 3.0 |
Fosinopril/pharmacology | 2 | 100.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
*Peptidyl-Dipeptidase A | 2 | 100.0 |
Hypertension, Renal/*drug therapy | 2 | 100.0 |
Captopril/administration & dosage/pharmacology/*therapeutic use | 2 | 100.0 |
Cyclic GMP/metabolism | 2 | 2.0 |
Collagen/*metabolism | 2 | 1.0 |
Peptidyl-Dipeptidase A/drug effects | 3 | 100.0 |
Furosemide/therapeutic use | 3 | 25.0 |
Proportional Hazards Models | 5 | 0.0 |
Hypertension/*complications/physiopathology | 3 | 50.0 |
Vascular Resistance/physiology | 3 | 13.0 |
Enalapril/pharmacology/therapeutic use | 2 | 100.0 |
Conserved Sequence | 2 | 0.0 |
Isoenzymes/*genetics | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Circadian Rhythm | 3 | 1.0 |
Spirometry | 2 | 6.0 |
Saralasin/pharmacology | 2 | 25.0 |
Heart Ventricles/physiopathology | 2 | 5.0 |
Hemodynamic Processes/*physiology | 4 | 12.0 |
Receptors, Angiotensin/physiology | 2 | 13.0 |
Cell Division/physiology | 3 | 0.0 |
Biphenyl Compounds/*adverse effects | 2 | 100.0 |
Lisinopril/*adverse effects | 3 | 100.0 |
Biphenyl Compounds/pharmacology | 7 | 25.0 |
Necrosis | 2 | 0.0 |
Kidney/physiology | 6 | 10.0 |
Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics/*pharmacology | 5 | 100.0 |
Lung/enzymology | 9 | 16.0 |
Hypertension/ethnology/*genetics | 3 | 25.0 |
Jamaica/epidemiology | 2 | 28.0 |
Atrial Natriuretic Factor/*metabolism | 2 | 15.0 |
Lisinopril/*therapeutic use | 2 | 22.0 |
von Willebrand Factor/analysis | 4 | 1.0 |
Kidney Failure, Acute/*chemically induced | 3 | 75.0 |
Lisinopril/administration & dosage/*therapeutic use | 2 | 100.0 |
Kidney/enzymology | 10 | 7.0 |
Sequence Analysis | 2 | 0.0 |
Blotting, Southern | 4 | 0.0 |
Muramidase/*blood | 5 | 45.0 |
Peroxidase/*blood | 2 | 4.0 |
Spectrophotometry | 3 | 1.0 |
Nuclear Magnetic Resonance, Biomolecular | 2 | 1.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Exercise | 5 | 4.0 |
Heart Failure, Congestive/*drug therapy/epidemiology | 2 | 66.0 |
Anesthesia | 2 | 6.0 |
Surgical Procedures, Operative | 2 | 14.0 |
Heart Failure, Congestive/*enzymology | 2 | 40.0 |
Isoquinolines/therapeutic use | 3 | 100.0 |
Arteriosclerosis/etiology/prevention & control | 2 | 50.0 |
Cardiomegaly/*drug therapy/etiology | 2 | 66.0 |
Plants, Medicinal | 2 | 4.0 |
Plants, Toxic | 2 | 5.0 |
Diabetes Mellitus, Type 2/complications/*physiopathology | 3 | 75.0 |
Sarcoidosis/enzymology | 2 | 66.0 |
*Hypotension, Controlled | 2 | 50.0 |
Sympathetic Nervous System/*physiopathology | 2 | 5.0 |
Prazosin/therapeutic use | 3 | 60.0 |
Sympathetic Nervous System/*drug effects/physiopathology | 2 | 100.0 |
Biopsy, Needle | 3 | 0.0 |
Hypertension/*enzymology | 2 | 20.0 |
Enalaprilat/administration & dosage/*pharmacology | 3 | 100.0 |
Pulmonary Wedge Pressure/drug effects | 2 | 50.0 |
Regional Blood Flow/drug effects | 17 | 15.0 |
Antigens, CD13 | 3 | 5.0 |
Diabetes Mellitus, Type 1/*enzymology | 2 | 18.0 |
Water-Electrolyte Balance/*drug effects | 3 | 18.0 |
Atrial Natriuretic Factor/*blood | 4 | 6.0 |
Kidney Failure, Chronic/complications/*therapy | 2 | 25.0 |
Hypertension, Renovascular/drug therapy | 11 | 100.0 |
*Radioisotope Renography | 2 | 28.0 |
Technetium Tc 99m Pentetate/*diagnostic use | 2 | 28.0 |
Peptidyl-Dipeptidase A/biosynthesis/*genetics/metabolism | 2 | 100.0 |
Rats, Inbred SHR/*genetics | 2 | 28.0 |
Rats, Inbred WKY/genetics | 2 | 66.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Factor Analysis, Statistical | 2 | 5.0 |
Hypertension/physiopathology/*therapy | 2 | 100.0 |
Memory/drug effects | 2 | 13.0 |
Isoquinolines/*pharmacology | 3 | 11.0 |
Calcium/blood | 2 | 0.0 |
Cell Division/*drug effects | 3 | 1.0 |
DNA/biosynthesis | 3 | 0.0 |
Indoles/pharmacology | 5 | 2.0 |
Kidney Failure, Chronic/*metabolism | 2 | 9.0 |
Osmolar Concentration | 4 | 0.0 |
Administration, Inhalation | 5 | 3.0 |
Acetylcholinesterase/blood | 2 | 7.0 |
Hypertension/blood/*drug therapy/physiopathology | 8 | 50.0 |
Carboxypeptidases A | 2 | 15.0 |
Carbohydrates/metabolism | 2 | 3.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Sodium, Dietary/administration & dosage | 2 | 22.0 |
Heart Failure, Congestive/*drug therapy/etiology | 2 | 100.0 |
Cell Adhesion Molecules/*metabolism | 2 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
*Promoter Regions (Genetics) | 5 | 0.0 |
Sheep | 3 | 0.0 |
Blood Proteins/metabolism | 4 | 1.0 |
Endothelium/cytology/metabolism | 2 | 11.0 |
C-Reactive Protein/analysis | 2 | 0.0 |
Dipeptides/administration & dosage/*therapeutic use | 2 | 100.0 |
Lisinopril | 38 | 95.0 |
Norepinephrine/*blood | 2 | 3.0 |
Hypertension, Renal/drug therapy | 4 | 80.0 |
Kidney Failure, Chronic/drug therapy | 3 | 50.0 |
Serum Albumin/metabolism | 3 | 1.0 |
Angiotensin II/*pharmacology/physiology | 3 | 50.0 |
Cell Count | 3 | 0.0 |
Peptide Fragments/isolation & purification | 2 | 3.0 |
Heart Failure, Congestive/physiopathology | 2 | 18.0 |
Angiotensin-Converting Enzyme Inhibitors/*blood | 2 | 100.0 |
Smoking/*metabolism | 2 | 4.0 |
Dipeptides/*pharmacology | 5 | 29.0 |
Hydrochlorothiazide/*pharmacology | 3 | 75.0 |
Forearm/*blood supply | 4 | 19.0 |
Angiotensin-Converting Enzyme Inhibitors/blood/*therapeutic use | 2 | 100.0 |
Endothelium/cytology | 2 | 5.0 |
Mast Cells/enzymology | 3 | 30.0 |
Kidney Failure, Chronic/complications/*metabolism | 2 | 40.0 |
Rest | 2 | 4.0 |
Budesonide | 3 | 30.0 |
Hydrocortisone/blood | 5 | 1.0 |
Pregnenediones/*administration & dosage | 2 | 40.0 |
Vital Capacity | 2 | 5.0 |
Macrophages/enzymology | 2 | 6.0 |
Autonomic Nervous System/drug effects | 2 | 40.0 |
Creatinine/blood/urine | 3 | 13.0 |
Cold/diagnostic use | 2 | 33.0 |
Coronary Vessels/*drug effects/physiology | 2 | 33.0 |
Culture Techniques | 2 | 0.0 |
Dipeptides/pharmacology | 4 | 9.0 |
Sarcoidosis/*metabolism | 2 | 28.0 |
Growth Hormone/genetics | 2 | 10.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
*Bicyclo Compounds, Heterocyclic | 2 | 50.0 |
Glomerular Filtration Rate/*drug effects | 2 | 28.0 |
*Preanesthetic Medication | 2 | 66.0 |
Heart/*physiopathology | 4 | 9.0 |
Myocardial Infarction/physiopathology | 2 | 28.0 |
Antihypertensive Agents/administration & dosage/therapeutic use | 2 | 66.0 |
Blood Pressure Monitors | 2 | 25.0 |
Enalapril/administration & dosage/*therapeutic use | 2 | 100.0 |
Molecular Conformation | 2 | 0.0 |
Remission, Spontaneous | 2 | 2.0 |
Sarcoidosis/*blood | 3 | 75.0 |
Enalapril/adverse effects | 4 | 100.0 |
Cardiac Output, Low/blood/*drug therapy/physiopathology | 3 | 100.0 |
Hormones/*blood | 4 | 2.0 |
Adrenergic alpha-Antagonists/therapeutic use | 4 | 80.0 |
*Cardiovascular Physiology | 2 | 7.0 |
Lung Diseases/diagnosis/enzymology | 2 | 100.0 |
Binding Sites/drug effects | 2 | 3.0 |
Cough/chemically induced | 4 | 80.0 |
Myocardial Ischemia/prevention & control | 2 | 66.0 |
Bradykinin/administration & dosage/*pharmacology | 2 | 100.0 |
Indoles/administration & dosage/*pharmacology | 3 | 50.0 |
Injections, Intradermal | 4 | 9.0 |
Death, Sudden, Cardiac/*prevention & control | 2 | 66.0 |
Angioneurotic Edema/*chemically induced/drug therapy | 2 | 100.0 |
Circadian Rhythm/physiology | 2 | 3.0 |
Hypertension/blood/*physiopathology | 3 | 15.0 |
Sodium/blood | 2 | 1.0 |
Muscle Contraction/*drug effects | 2 | 8.0 |
Neprilysin/antagonists & inhibitors | 2 | 50.0 |
Hypertension/blood/drug therapy | 3 | 37.0 |
Diabetic Nephropathies/enzymology | 2 | 40.0 |
Urea/urine | 2 | 33.0 |
Furosemide/*pharmacology | 2 | 40.0 |
Muscle, Smooth/*drug effects | 2 | 13.0 |
Potassium/*blood | 4 | 26.0 |
Kidney Failure, Acute/chemically induced | 2 | 33.0 |
Kidney Transplantation | 2 | 1.0 |
Angiotensin I/pharmacology | 6 | 54.0 |
Brain/enzymology | 3 | 1.0 |
Angiotensin-Converting Enzyme Inhibitors | 32 | 94.0 |
Blood Vessels/*enzymology | 2 | 50.0 |
Dipeptides | 2 | 50.0 |
Cardiomegaly/drug therapy | 4 | 100.0 |
Diuretics, Thiazide/*therapeutic use | 2 | 66.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Methods | 5 | 2.0 |
Cell Movement | 2 | 0.0 |
*Cloning, Molecular | 2 | 0.0 |
Endothelium, Vascular/*cytology | 2 | 1.0 |
Enalapril/adverse effects/analogs & derivatives | 2 | 100.0 |
Bicyclo Compounds/pharmacology | 3 | 100.0 |
Kidney/drug effects/physiology | 3 | 33.0 |
Ramipril | 26 | 100.0 |
Benzazepines/*pharmacology | 2 | 13.0 |
Lower Body Negative Pressure | 4 | 33.0 |
Capsules | 2 | 4.0 |
Potassium/urine | 2 | 5.0 |
Diabetes Mellitus, Type 2/complications | 2 | 9.0 |
Enzyme Tests | 4 | 5.0 |
Adrenergic beta-Antagonists/administration & dosage/*therapeutic use | 2 | 100.0 |
Cyclic GMP/blood | 2 | 14.0 |
Heart Failure, Congestive/*drug therapy/metabolism/physiopathology | 2 | 66.0 |
Bicyclo Compounds/*therapeutic use | 2 | 100.0 |
Pancreatic Elastase/*blood | 2 | 10.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Biomechanics | 3 | 2.0 |
Fosinopril | 6 | 100.0 |
Cyclic AMP/blood | 2 | 5.0 |
Epoprostenol/*biosynthesis | 7 | 29.0 |
Muscle, Smooth, Vascular/drug effects/*metabolism | 2 | 8.0 |
Proline/*analogs & derivatives/pharmacology | 4 | 23.0 |
Karyotyping | 2 | 0.0 |
Propranolol/therapeutic use | 2 | 18.0 |
Endothelium/cytology/enzymology | 2 | 50.0 |
Isoquinolines/administration & dosage/*therapeutic use | 2 | 66.0 |
Free Radicals | 3 | 1.0 |
Iodohippuric Acid/diagnostic use | 2 | 66.0 |
Technetium Tc 99m Pentetate/diagnostic use | 2 | 28.0 |
Cardiovascular Diseases/*epidemiology | 2 | 15.0 |
Cilazapril | 21 | 100.0 |
Monitoring, Physiologic | 4 | 4.0 |
Pyridazines/*pharmacology | 4 | 66.0 |
Bicyclo Compounds/*pharmacology | 7 | 77.0 |
Isoelectric Point | 2 | 1.0 |
Enalapril/analogs & derivatives/therapeutic use | 2 | 100.0 |
Heart Failure, Congestive/therapy | 2 | 50.0 |
Reflex/*drug effects | 4 | 44.0 |
Sulfhydryl Compounds/*pharmacology | 2 | 20.0 |
Angiotensin-Converting Enzyme Inhibitors/blood/*pharmacokinetics | 2 | 100.0 |
Blood Pressure Determination/methods | 2 | 25.0 |
Diabetes Mellitus, Type 2/*complications/drug therapy | 2 | 66.0 |
Kidney/blood supply/*drug effects | 2 | 100.0 |
Rats, Inbred Strains | 15 | 1.0 |
Hypertension/*drug therapy/physiopathology/urine | 2 | 100.0 |
Kallikreins/*urine | 2 | 22.0 |
Indans/adverse effects/*therapeutic use | 2 | 100.0 |
Enalapril/adverse effects/*therapeutic use | 3 | 50.0 |
Hypertension, Renal/complications/drug therapy | 2 | 100.0 |
Pyridazines/pharmacology | 3 | 37.0 |
Glutamyl Aminopeptidase | 2 | 22.0 |
Lung Neoplasms/*enzymology | 2 | 8.0 |
Sarcoidosis/*enzymology | 12 | 80.0 |
Peptidyl-Dipeptidase A/analysis/*blood | 2 | 100.0 |
Hypothyroidism/*enzymology | 2 | 66.0 |
Radioisotope Renography | 4 | 66.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
*Free Radical Scavengers | 2 | 15.0 |
Diabetic Nephropathies/*physiopathology | 3 | 27.0 |
Kidney Glomerulus/drug effects/physiopathology | 2 | 100.0 |
Albumins/analysis | 2 | 5.0 |
Neutrophils | 2 | 2.0 |
Pulmonary Artery/physiology | 2 | 40.0 |
Electrolytes/metabolism | 2 | 11.0 |
Diabetic Nephropathies/etiology/physiopathology | 2 | 100.0 |
Kidney Failure, Acute/blood/*chemically induced | 2 | 100.0 |
Enalapril/analogs & derivatives/pharmacology | 6 | 100.0 |
*Models, Molecular | 2 | 1.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Fibrinolytic Agents/therapeutic use | 2 | 11.0 |
Organophosphorus Compounds/*pharmacology | 2 | 9.0 |
Blood Vessels/physiology | 2 | 22.0 |
Bridged Compounds/*pharmacology | 7 | 70.0 |
Cats | 2 | 0.0 |
Factor VIII/analysis | 2 | 1.0 |
Cerebrovascular Circulation/*drug effects | 3 | 18.0 |
Adrenergic beta-Antagonists/pharmacology | 2 | 10.0 |
Chemistry | 8 | 3.0 |
Angiotensin II/blood/*physiology | 2 | 100.0 |
Bicyclo Compounds/adverse effects/*therapeutic use | 3 | 100.0 |
Bridged Compounds/*therapeutic use | 9 | 90.0 |
Xamoterol | 5 | 83.0 |
Water-Electrolyte Balance/drug effects | 3 | 21.0 |
Breast Neoplasms/*enzymology/*genetics | 2 | 11.0 |
Ethnic Groups | 3 | 1.0 |
Atenolol/*pharmacology | 2 | 33.0 |
Proteinuria | 2 | 5.0 |
*Kidney Function Tests | 2 | 16.0 |
*Glomerular Filtration Rate | 2 | 8.0 |
Technetium Tc 99m Dimercaptosuccinic Acid | 2 | 50.0 |
Kinins/*blood | 5 | 50.0 |
Kinins/*physiology | 3 | 60.0 |
*HIV-1 | 2 | 0.0 |
Exertion | 2 | 2.0 |
Atrial Natriuretic Factor/blood/*drug effects | 3 | 100.0 |
Pyridazines/*therapeutic use | 4 | 80.0 |
Prostaglandins E/*urine | 2 | 28.0 |
Hypertension/metabolism/*physiopathology | 2 | 33.0 |
Norepinephrine/administration & dosage/blood | 2 | 100.0 |
Angiotensin-Converting Enzyme Inhibitors/adverse effects/*pharmacology | 2 | 66.0 |
Kidney Failure, Chronic/*prevention & control | 3 | 100.0 |
Hypertension, Renovascular/*drug therapy | 3 | 100.0 |
Glomerulonephritis, IGA/*drug therapy | 2 | 66.0 |
*Stents | 5 | 7.0 |
Technetium/diagnostic use | 2 | 7.0 |
Technetium Tc 99m Pentetate | 2 | 50.0 |
Sodium/deficiency | 2 | 100.0 |
Callithrix | 2 | 2.0 |
*Oligopeptides | 2 | 14.0 |
Metoprolol/*therapeutic use | 2 | 40.0 |
Skin/*drug effects | 2 | 13.0 |
Enalaprilat | 13 | 92.0 |
Vasectomy | 2 | 18.0 |
World Health Organization | 2 | 2.0 |
Kallikreins/*physiology | 2 | 50.0 |
Adrenergic beta-Agonists/*therapeutic use | 3 | 30.0 |
Diuresis/drug effects | 2 | 8.0 |
Heart Failure, Congestive/*metabolism | 2 | 7.0 |
*Ramipril/*analogs & derivatives | 3 | 100.0 |
Enalapril/*analogs & derivatives/pharmacology | 2 | 100.0 |
*Exercise Therapy | 2 | 7.0 |
Oxygen/blood | 4 | 3.0 |
Enalapril/*analogs & derivatives/therapeutic use | 2 | 40.0 |
Anoxia/*blood | 2 | 13.0 |
*African Americans | 3 | 13.0 |
Socioeconomic Factors | 3 | 1.0 |
Inhibitory Concentration 50 | 3 | 1.0 |
*Phytotherapy | 2 | 2.0 |
*Epistasis, Genetic | 3 | 12.0 |
*Renin-Angiotensin System/drug effects | 4 | 66.0 |
Gallium Radioisotopes/*diagnostic use | 3 | 27.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
Pulmonary Fibrosis/metabolism | 2 | 20.0 |
Drug Eruptions/etiology | 2 | 28.0 |
Epidemiology, Molecular | 2 | 2.0 |
Sperm Motility/*drug effects | 2 | 11.0 |
Endopeptidases/pharmacology | 2 | 10.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Isoproterenol/pharmacology | 2 | 1.0 |
Bronchi | 2 | 16.0 |
Irrigation | 8 | 14.0 |
Pulmonary Alveoli | 2 | 25.0 |
Peptidyl-Dipeptidase A/*isolation & purification | 3 | 100.0 |
Kidney/*radionuclide imaging | 2 | 100.0 |
Benzazepines/pharmacology | 2 | 18.0 |
*Smoking | 3 | 3.0 |
Peptidyl-Dipeptidase A/blood/*cerebrospinal fluid | 2 | 66.0 |
Sarcoidosis/blood/*enzymology | 2 | 100.0 |
Immunochemistry | 3 | 1.0 |
Methylenetetrahydrofolate Reductase (NADPH2)/*genetics | 2 | 1.0 |
Bronchi/enzymology | 2 | 50.0 |
Pulmonary Alveoli/enzymology | 2 | 40.0 |
Endopeptidases/*blood | 3 | 25.0 |
Peptidyl-Dipeptidase A/isolation & purification/*metabolism | 2 | 100.0 |
Teprotide/pharmacology | 2 | 100.0 |
Furosemide/pharmacology | 2 | 13.0 |
Hypertension/*enzymology/physiopathology | 2 | 66.0 |
Enalapril/adverse effects/*analogs & derivatives/therapeutic use | 2 | 50.0 |
Sarcoidosis/*pathology | 2 | 40.0 |
Neutropenia/chemically induced | 2 | 5.0 |
Trypsin/pharmacology | 2 | 1.0 |
Peptidyl-Dipeptidase A/urine | 2 | 100.0 |
Teprotide | 2 | 100.0 |
Propranolol/pharmacology | 3 | 6.0 |
Placenta/*enzymology | 3 | 3.0 |
Insulin Resistance/physiology | 2 | 4.0 |
Mechanoreceptors/*physiology | 2 | 20.0 |
Dipeptides/blood/*therapeutic use | 2 | 100.0 |
Enalapril | 12 | 92.0 |
Dipeptides/adverse effects/*therapeutic use | 3 | 100.0 |
Proline/*analogs & derivatives | 8 | 66.0 |
Cyclophosphamide/therapeutic use | 2 | 2.0 |
Podophyllotoxin/*analogs & derivatives | 2 | 100.0 |
Lung/pathology | 2 | 2.0 |
Obesity/complications | 2 | 4.0 |
Neurotensin/*metabolism | 2 | 33.0 |
Leukocyte Count | 3 | 0.0 |
Cross Reactions | 2 | 0.0 |
*Altitude | 2 | 3.0 |
Glomerulonephritis/enzymology | 2 | 50.0 |
Macrophages/cytology/*enzymology | 2 | 66.0 |
Monocytes/cytology/*enzymology | 2 | 25.0 |
Isoelectric Focusing | 3 | 0.0 |
*Enzyme Tests | 2 | 3.0 |
Spermatogenesis | 2 | 3.0 |
Prednisone/therapeutic use | 3 | 2.0 |
Sarcoidosis/drug therapy/*enzymology | 2 | 100.0 |
*Drug Utilization Review | 2 | 50.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Asthma/*enzymology | 2 | 33.0 |
Hippurates/metabolism | 2 | 100.0 |
Drug Delivery Systems/methods | 2 | 13.0 |
Amyloid beta-Protein Precursor/genetics | 2 | 4.0 |
tau Proteins/genetics | 2 | 28.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
*Quantitative Trait Loci | 2 | 12.0 |
